Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
HIV-1-LTR	I-DNA
)	I-DNA
CAT	I-DNA
constructs	I-DNA
transfected	O
into	O
monocyte/macrophage-like	B-cell_line
cell	I-cell_line
lines	I-cell_line
but	O
not	O
a	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	B-protein
B	I-protein
in	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	B-cell_line
infected	I-cell_line
monocyte/macrophage-like	I-cell_line
cloned	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
U1	B-cell_line
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	B-RNA
RNA	I-RNA
and	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O

Lipopolysaccharide	NULL
Is	NULL
a	NULL
Potent	NULL
Monocyte/	NULL
Macrophage-specific	NULL
Stimulator	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Expression	NULL
By	NULL
Roger	NULL
J.	NULL
Pomerantz	NULL
,	NULL
``	NULL
t	NULL
Mark	NULL
B.	NULL
Feinberg	NULL
,	NULL
``	NULL
Didier	NULL
Trono	NULL
,	NULL
*	NULL
and	NULL
David	NULL
Baltimore*	NULL
From	NULL
the	NULL
*Whitehead	NULL
Institute	NULL
for	NULL
Biomedical	NULL
Research	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
02142	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Biology	NULL
,	NULL
Massachusetts	NULL
Institute	NULL
of	NULL
Technology	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
02139	NULL
;	NULL
and	NULL
the	NULL
HInfectious	NULL
Disease	NULL
Division	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02114	NULL
Summary	NULL
Lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
potently	NULL
stimulates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-long	NULL
terminal	NULL
repeat	NULL
(	NULL
HIV-1-LTR	NULL
)	NULL
CAT	NULL
constructs	NULL
transfected	NULL
into	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
but	NULL
not	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

This	NULL
effect	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
demonstrate	NULL
that	NULL
LPS	NULL
induces	NULL
a	NULL
DNA	NULL
binding	NULL
activity	NULL
indistinguishable	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
.	NULL

LPS	NULL
is	NULL
also	NULL
shown	NULL
to	NULL
dramatically	NULL
increase	NULL
HIV-1	NULL
production	NULL
from	NULL
a	NULL
chronically	NULL
infected	NULL
monocyte/macrophage-like	NULL
cloned	NULL
cell	NULL
line	NULL
,	NULL
U1	NULL
,	NULL
which	NULL
produces	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
HIV-1	NULL
at	NULL
baseline	NULL
.	NULL

The	NULL
stimulation	NULL
of	NULL
viral	NULL
production	NULL
from	NULL
this	NULL
cell	NULL
line	NULL
occurs	NULL
only	NULL
if	NULL
these	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
before	NULL
treatment	NULL
with	NULL
LPS	NULL
.	NULL

This	NULL
stimulation	NULL
of	NULL
HIV-1	NULL
production	NULL
is	NULL
correlated	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
HIV-1	NULL
RNA	NULL
and	NULL
an	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

LPS	NULL
is	NULL
not	NULL
able	NULL
to	NULL
induce	NULL
HIV-1	NULL
production	NULL
in	NULL
a	NULL
cloned	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
LPS	NULL
on	NULL
HIV-1	NULL
replication	NULL
occurs	NULL
at	NULL
picogram	NULL
per	NULL
milliliter	NULL
concentrations	NULL
and	NULL
may	NULL
be	NULL
clinically	NULL
significant	NULL
in	NULL
understanding	NULL
the	NULL
variability	NULL
of	NULL
the	NULL
natural	NULL
history	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Control	NULL
of	NULL
the	NULL
replication	NULL
of	NULL
HIV-1	NULL
involves	NULL
both	NULL
virus-encoded	NULL
proteins	NULL
and	NULL
cellular	NULL
factors	NULL
activated	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
exogenous	NULL
stimuli	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
cellular	NULL
events	NULL
is	NULL
evident	NULL
because	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
within	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
®	NULL
is	NULL
produced	NULL
by	NULL
various	NULL
cellular	NULL
stimuli	NULL
including	NULL
phorbol	NULL
esters	NULL
,	NULL
TNF-	NULL
,	NULL
and	NULL
heterolo-gous	NULL
viral	NULL
proteins	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
agents	NULL
appear	NULL
to	NULL
function	NULL
through	NULL
the	NULL
activation	NULL
of	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-KB	NULL
)	NULL
which	NULL
binds	NULL
to	NULL
two	NULL
11	NULL
bp	NULL
motifs	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
consequently	NULL
activates	NULL
LTR-driven	NULL
RNA	NULL
transcription	NULL
(	NULL
3-7	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
certain	NULL
cellular	NULL
stimuli	NULL
on	NULL
HIV-1	NULL
replication	NULL
have	NULL
been	NULL
studied	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
of	NULL
the	NULL
HIV-1-LTR	NULL
linked	NULL
to	NULL
reporter	NULL
genes	NULL
and	NULL
by	NULL
utilizing	NULL
chronically	NULL
infected	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
cells	NULL
(	NULL
3-14	NULL
)	NULL
.	NULL

HIV-1	NULL
growth	NULL
in	NULL
infected	NULL
people	NULL
is	NULL
difficult	NULL
to	NULL
study	NULL
directly	NULL
and	NULL
so	NULL
must	NULL
be	NULL
modeled	NULL
by	NULL
examining	NULL
influences	NULL
on	NULL
cells	NULL
in	NULL
culture	NULL
.	NULL

Factors	NULL
that	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
in	NULL
cell	NULL
culture	NULL
may	NULL
also	NULL
regulate	NULL
HIV-1	NULL
expression	NULL
in	NULL
CD4	NULL
lymphocytes	NULL
and	NULL
monocytes/macrophages	NULL
in	NULL
vivo	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

These	NULL
are	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte/mactrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
NF-KB	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
.	NULL

the	NULL
two	NULL
major	NULL
cell	NULL
types	NULL
known	NULL
to	NULL
harbor	NULL
HIV-1	NULL
(	NULL
1	NULL
)	NULL
.	NULL

In	NULL
the	NULL
periphery	NULL
,	NULL
CD4	NULL
lymphocytes	NULL
carry	NULL
most	NULL
of	NULL
the	NULL
virus	NULL
(	NULL
15	NULL
)	NULL
,	NULL
but	NULL
the	NULL
monocyte/macrophage	NULL
may	NULL
be	NULL
the	NULL
major	NULL
cell	NULL
type	NULL
infected	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
and	NULL
other	NULL
tissues	NULL
(	NULL
1	NULL
,	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

The	NULL
monocyte/macrophage	NULL
may	NULL
act	NULL
as	NULL
a	NULL
``	NULL
Trojan	NULL
Horse	NULL
,	NULL
``	NULL
concealing	NULL
the	NULL
virus	NULL
from	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
and	NULL
it	NULL
may	NULL
be	NULL
among	NULL
the	NULL
first	NULL
cells	NULL
infected	NULL
by	NULL
HIV-1	NULL
in	NULL
patients	NULL
(	NULL
1	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Many	NULL
agents	NULL
that	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
do	NULL
so	NULL
in	NULL
both	NULL
T	NULL
cells	NULL
and	NULL
monocyte/macrophages	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
granulocyte/macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
agents	NULL
that	NULL
induce	NULL
HIV-1	NULL
replication	NULL
only	NULL
in	NULL
monocyte/macrophages	NULL
are	NULL
not	NULL
well	NULL
described	NULL
(	NULL
9	NULL
,	NULL
12	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Stimuli	NULL
that	NULL
selectively	NULL
affect	NULL
HIV-1	NULL
replication	NULL
in	NULL
monocyte/macrophages	NULL
might	NULL
,	NULL
therefore	NULL
,	NULL
hold	NULL
significant	NULL
clinical	NULL
importance	NULL
.	NULL

The	NULL
monocyte/macrophage	NULL
can	NULL
be	NULL
studied	NULL
either	NULL
directly	NULL
after	NULL
culturing	NULL
or	NULL
through	NULL
cell	NULL
line	NULL
models	NULL
.	NULL

Primary	NULL
monocyte/macrophages	NULL
have	NULL
thus	NULL
far	NULL
been	NULL
refractory	NULL
to	NULL
transfection	NULL
with	NULL
significant	NULL
efficiency	NULL
,	NULL
and	NULL
therefore	NULL
,	NULL
are	NULL
not	NULL
suitable	NULL
for	NULL
the	NULL
study	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
regulation	NULL
.	NULL

We	NULL
have	NULL
thus	NULL
chosen	NULL
to	NULL
study	NULL
the	NULL
U937	NULL
and	NULL
THP-1	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
as	NULL
model	NULL
systems	NULL
.	NULL

253	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
«	NULL
0022-1007/90/07/0253/09	NULL
$	NULL
2.00	NULL
Volume	NULL
172	NULL
July	NULL
1990	NULL
253-261	NULL
In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
LPS	NULL
or	NULL
endotoxin	NULL
,	NULL
a	NULL
constituent	NULL
of	NULL
the	NULL
cell	NULL
wall	NULL
of	NULL
gram-negative	NULL
bacteria	NULL
,	NULL
stimulates	NULL
gene	NULL
expression	NULL
directed	NULL
from	NULL
the	NULL
HIV-1-LT	NULL
R	NULL
in	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

LPS	NULL
has	NULL
this	NULL
effect	NULL
at	NULL
physiologically	NULL
significant	NULL
concentrations	NULL
and	NULL
appears	NULL
to	NULL
do	NULL
so	NULL
through	NULL
the	NULL
activation	NULL
of	NULL
NF-KB	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
binds	NULL
to	NULL
two	NULL
«	NULL
B	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
the	NULL
HIV-A-LTR	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Contrary	NULL
to	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
7	NULL
)	NULL
,	NULL
we	NULL
find	NULL
no	NULL
correlation	NULL
between	NULL
the	NULL
state	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
available	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
level	NULL
of	NULL
constitutive	NULL
expression	NULL
of	NULL
activated	NULL
NF-	NULL
«	NULL
xB	NULL
.	NULL

However	NULL
,	NULL
we	NULL
do	NULL
find	NULL
that	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
LPS	NULL
and	NULL
consequent	NULL
stimulation	NULL
of	NULL
HIV-1	NULL
from	NULL
a	NULL
cloned	NULL
monocyte/macrophage-like	NULL
cell	NULL
line	NULL
(	NULL
9	NULL
)	NULL
occur	NULL
only	NULL
after	NULL
treatment	NULL
with	NULL
GM-CSF	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
developmental	NULL
maturity	NULL
of	NULL
HIV-1-infected	NULL
monocyte	NULL
populations	NULL
may	NULL
determine	NULL
whether	NULL
they	NULL
respond	NULL
to	NULL
LPS	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
HIV-1	NULL
production	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cells	NULL
.	NULL

_	NULL
A	NULL
monoblastoid	NULL
cell	NULL
line	NULL
,	NULL
U937	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
penicillin	NULL
(	NULL
250	NULL
U/mi	NULL
)	NULL
,	NULL
and	NULL
streptomycin	NULL
(	NULL
250	NULL
ug/ml	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
line	NULL
THP-I	NULL
,	NULL
derived	NULL
from	NULL
monocytic	NULL
leukemic	NULL
cells	NULL
,	NULL
was	NULL
maintained	NULL
as	NULL
above	NULL
(	NULL
19	NULL
)	NULL
.	NULL

A	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
Jurkat	NULL
was	NULL
also	NULL
maintained	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

A	NULL
subclone	NULL
of	NULL
HIV-1-infected	NULL
U937	NULL
cells	NULL
,	NULL
U1	NULL
,	NULL
was	NULL
donated	NULL
by	NULL
Thomas	NULL
Folks	NULL
and	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Program	NULL
,	NULL
NIAID	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
.	NULL

This	NULL
cell	NULL
line	NULL
shows	NULL
a	NULL
minimal	NULL
amount	NULL
of	NULL
constitutive	NULL
expression	NULL
of	NULL
HIV-1	NULL
(	NULL
9	NULL
)	NULL
.	NULL

A	NULL
variant	NULL
of	NULL
the	NULL
CEM	NULL
T-cell	NULL
line	NULL
,	NULL
A3.01	NULL
,	NULL
was	NULL
infected	NULL
with	NULL
the	NULL
LAV	NULL
strain	NULL
of	NULL
HIV-1	NULL
and	NULL
a	NULL
subclone	NULL
,	NULL
ACH-2	NULL
,	NULL
was	NULL
obtained	NULL
that	NULL
exhibits	NULL
minimal	NULL
amounts	NULL
of	NULL
constitutive	NULL
expression	NULL
of	NULL
HIV-1	NULL
(	NULL
10	NULL
)	NULL
.	NULL

This	NULL
cell	NULL
line	NULL
was	NULL
donated	NULL
by	NULL
Thomas	NULL
Folks	NULL
and	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Program	NULL
,	NULL
NIAID	NULL
,	NULL
NIH	NULL
.	NULL

Plasmids	NULL
.	NULL

-	NULL
The	NULL
plasmid	NULL
HIV-CAT	NULL
,	NULL
containing	NULL
the	NULL
HIV-A-LTR	NULL
upstream	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyl	NULL
transferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
has	NULL
been	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
,	NULL
HIV	NULL
NF-	NULL
«	NULL
B	NULL
A	NULL
CAT	NULL
,	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
NF-KB	NULL
sites	NULL
,	NULL
rendering	NULL
these	NULL
sites	NULL
unable	NULL
to	NULL
bind	NULL
the	NULL
NH-	NULL
«	NULL
B	NULL
protein	NULL
,	NULL
has	NULL
also	NULL
previously	NULL
been	NULL
described	NULL
(	NULL
4	NULL
)	NULL
.	NULL

A	NULL
plasmid	NULL
(	NULL
J18	NULL
)	NULL
containing	NULL
two	NULL
B	NULL
sites	NULL
from	NULL
the	NULL
x	NULL
enhancer	NULL
which	NULL
were	NULL
cloned	NULL
into	NULL
Hind	NULL
III	NULL
and	NULL
Sal	NULL
I	NULL
sites	NULL
upstream	NULL
of	NULL
a	NULL
truncated	NULL
mouse	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
J	NULL
.	NULL

Pierce	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
c-fos	NULL
promoter	NULL
was	NULL
truncated	NULL
to	NULL
nucleotide	NULL
56	NULL
to	NULL
remove	NULL
phorbol	NULL
ester	NULL
and	NULL
serum-responsive	NULL
ele-ments	NULL
.	NULL

A	NULL
plasmid	NULL
lacking	NULL
«	NULL
B	NULL
sites	NULL
but	NULL
retaining	NULL
the	NULL
truncated	NULL
c-fos	NULL
promoter	NULL
was	NULL
also	NULL
obtained	NULL
from	NULL
J	NULL
.	NULL

Pierce	NULL
,	NULL
Whitehead	NULL
Institute	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Transfections	NULL
and	NULL
CAT	NULL
Assays	NULL
.	NULL

_	NULL
All	NULL
cell	NULL
lines	NULL
were	NULL
transfected	NULL
using	NULL
DEAE-dextran	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
serum-free	NULL
suspension	NULL
Tris-buffered	NULL
saline	NULL
(	NULL
22	NULL
)	NULL
.	NULL

10°	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
DEAE-Dextran	NULL
at	NULL
200	NULL
pg/ml	NULL
(	NULL
Phar-macia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
containing	NULL
10	NULL
ug	NULL
of	NULL
plasmid	NULL
in	NULL
1	NULL
ml	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
90	NULL
min	NULL
at	NULL
37°C	NULL
with	NULL
frequent	NULL
mixing	NULL
.	NULL

A	NULL
10	NULL
%	NULL
DMSO	NULL
shock	NULL
was	NULL
performed	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
and	NULL
then	NULL
resuspended	NULL
to	NULL
a	NULL
concentration	NULL
of	NULL
5	NULL
x	NULL
10°	NULL
cells/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
either	NULL
LPS	NULL
Escherichia	NULL
coli	NULL
0127	NULL
:	NULL
B8	NULL
(	NULL
Difco	NULL
Laboratories	NULL
,	NULL
Detroit	NULL
,	NULL
MI	NULL
)	NULL
,	NULL
recombinant	NULL
human	NULL
TNF-a	NULL
(	NULL
Genzyme	NULL
Corp.	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Some	NULL
transfections	NULL
received	NULL
no	NULL
treatments	NULL
.	NULL

A	NULL
rabbit	NULL
anti-human	NULL
TNF-	NULL
@	NULL
neutralizing	NULL
antibody	NULL
(	NULL
1	NULL
pul	NULL
neutralizes	NULL
10°	NULL
U.of	NULL
TNF-	NULL
)	NULL
was	NULL
also	NULL
added	NULL
to	NULL
some	NULL
transfections	NULL
(	NULL
Genzyme	NULL
Corp.	NULL
)	NULL
.	NULL

44	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
CAT	NULL
assay	NULL
and	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
(	NULL
23	NULL
)	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
quantity	NULL
of	NULL
protein	NULL
used	NULL
per	NULL
assay	NULL
was	NULL
normalized	NULL
(	NULL
70	NULL
ug	NULL
for	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
and	NULL
100	NULL
ug	NULL
for	NULL
Jurkat	NULL
cells	NULL
)	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
.	NULL

Percent	NULL
conversion	NULL
of	NULL
acetylated	NULL
products	NULL
by	NULL
liquid	NULL
scintillation	NULL
was	NULL
calculated	NULL
.	NULL

Transfections	NULL
were	NULL
performed	NULL
between	NULL
two	NULL
and	NULL
six	NULL
times	NULL
and	NULL
results	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
arithmetic	NULL
mean	NULL
+	NULL
SEM	NULL
.	NULL

Cellular	NULL
Extracts	NULL
and	NULL
Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

Cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
5	NULL
x	NULL
10	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
treatment	NULL
for	NULL
various	NULL
time	NULL
periods	NULL
with	NULL
GM-CSF	NULL
(	NULL
Genetics	NULL
Institute	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
,	NULL
LPS	NULL
,	NULL
or	NULL
PMA	NULL
plus	NULL
PHA	NULL
according	NULL
to	NULL
a	NULL
protocol	NULL
,	NULL
with	NULL
some	NULL
modifications	NULL
,	NULL
described	NULL
by	NULL
Baeuerle	NULL
and	NULL
Baltimore	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
ice-cold	NULL
PBS	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
that	NULL
consisted	NULL
of	NULL
20	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.35	NULL
M	NULL
NaCl	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
NP-40	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
;	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
0.3	NULL
ug/	NULL
mi	NULL
antipain	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
0.3	NULL
ug/ml	NULL
leupeptin	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

After	NULL
lysis	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
,	NULL
particulate	NULL
material	NULL
was	NULL
removed	NULL
by	NULL
centrifuga-tion	NULL
at	NULL
11,000	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
's	NULL
protein	NULL
content	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
assay	NULL
using	NULL
bicinchoninic	NULL
acid	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Pierce	NULL
Chemical	NULL
Co.	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
analyses	NULL
to	NULL
detect	NULL
NF-KB	NULL
binding	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
P-labeled	NULL
DNA	NULL
probe	NULL
was	NULL
a	NULL
44-bp	NULL
HindIII-Sall	NULL
fragment	NULL
cut	NULL
from	NULL
a	NULL
plasmid	NULL
(	NULL
J10	NULL
)	NULL
,	NULL
containing	NULL
a	NULL
single	NULL
«	NULL
B	NULL
enhancer	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
mouse	NULL
c-fos	NULL
promoter	NULL
(	NULL
21	NULL
)	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
end-labeled	NULL
with	NULL
[	NULL
PJCTP	NULL
and	NULL
[	NULL
P	NULL
]	NULL
ATP	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
using	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
E.	NULL
coli	NULL
DNA	NULL
polymerase	NULL
I	NULL
(	NULL
Boehringer-Mannheim	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Bands	NULL
other	NULL
than	NULL
free	NULL
probe	NULL
and	NULL
NK-	NULL
«	NULL
B	NULL
activity	NULL
are	NULL
noted	NULL
with	NULL
cellular	NULL
extracts	NULL
made	NULL
with	NULL
this	NULL
method	NULL
.	NULL

They	NULL
represent	NULL
cytoplasmic	NULL
DNA	NULL
binding	NULL
proteins	NULL
and/or	NULL
proteolytic	NULL
digestion	NULL
products	NULL
of	NULL
nuclear	NULL
proteins	NULL
(	NULL
Feinberg	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

The	NULL
competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
various	NULL
nanogram	NULL
amounts	NULL
of	NULL
an	NULL
unlabeled	NULL
double-stranded	NULL
oligonucleotide	NULL
containing	NULL
both	NULL
HIV-1	NULL
NF-	NULL
«	NULL
B-binding	NULL
motifs	NULL
and	NULL
an	NULL
oligonucleotide	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
HIV-1	NULL
NF-	NULL
«	NULL
B-binding	NULL
motifs	NULL
,	NULL
previously	NULL
shown	NULL
to	NULL
not	NULL
bind	NULL
NF-KB	NULL
(	NULL
4	NULL
)	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
M.	NULL
Lenardo	NULL
}	NULL
)	NULL
.	NULL

HIV-1	NULL
«	NULL
B	NULL
oligonucleotide	NULL
:	NULL
5STCGACAAGGGACTTTCCGCTG-GGGACTTTCCAGGGC3	NULL
'	NULL
.	NULL

Mutant	NULL
HIV-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
:	NULL
STCGACAACTCACTTTCCGCTGCTCACTTTCCAGGC3	NULL
.	NULL

Stimulation	NULL
of	NULL
HIVA	NULL
Expression	NULL
from	NULL
U1	NULL
and	NULL
ACH-2	NULL
Cell	NULL
Lines	NULL
.	NULL

5	NULL
x	NULL
10°	NULL
were	NULL
seeded	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
medium	NULL
in	NULL
24-well	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

They	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
a	NULL
variety	NULL
of	NULL
agents	NULL
were	NULL
added	NULL
including	NULL
TNF-	NULL
«	NULL
,	NULL
LPS	NULL
,	NULL
and	NULL
PMA	NULL
plus	NULL
PHA	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
samples	NULL
of	NULL
supernatants	NULL
were	NULL
removed	NULL
daily	NULL
for	NULL
3	NULL
d.	NULL
The	NULL
p24	NULL
antigen	NULL
level	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
sensitive	NULL
ELISA	NULL
method	NULL
(	NULL
Dupont	NULL
,	NULL
Wilmington	NULL
,	NULL
DE	NULL
)	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
instruc-tions	NULL
.	NULL

Some	NULL
cultures	NULL
were	NULL
pretreated	NULL
with	NULL
GM-CSF	NULL
for	NULL
24	NULL
h	NULL
before	NULL
other	NULL
agents	NULL
were	NULL
added	NULL
.	NULL

neutralizing	NULL
antibody	NULL
(	NULL
Genzyme	NULL
Corp.	NULL
)	NULL
was	NULL
added	NULL
where	NULL
indicated	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
twice	NULL
using	NULL
duplicate	NULL
or	NULL
triplicate	NULL
samples	NULL
per	NULL
experiment	NULL
.	NULL

Data	NULL
presented	NULL
represent	NULL
the	NULL
arithmetic	NULL
mean	NULL
+	NULL
SEM	NULL
.	NULL

254	NULL
Lipopolysaccharide	NULL
and	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Results	NULL
Activation	NULL
of	NULL
HIV1-LTR	NULL
by	NULL
LPS	NULL
in	NULL
Monocyte/Macrophage-like	NULL
Cell	NULL
Lines	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
LPS	NULL
on	NULL
HIV-1-LTR-directed	NULL
gene	NULL
expression	NULL
,	NULL
various	NULL
cell	NULL
lines	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
HIV-1-LTR	NULL
CAT	NULL
construct	NULL
.	NULL

LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
!	NULL
)	NULL

greatly	NULL
increased	NULL
the	NULL
amount	NULL
of	NULL
CAT	NULL
activity	NULL
produced	NULL
from	NULL
this	NULL
HIV-1-LTR	NULL
CAT	NULL
construct	NULL
after	NULL
transient	NULL
transfection	NULL
of	NULL
both	NULL
U937	NULL
,	NULL
and	NULL
the	NULL
phenotypically	NULL
more	NULL
mature	NULL
THP-1	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

PMA	NULL
plus	NULL
PHA	NULL
(	NULL
50	NULL
ng/ml	NULL
and	NULL
2	NULL
ug/ml	NULL
)	NULL
and	NULL
TNF-a	NULL
(	NULL
1,000	NULL
U/ml	NULL
)	NULL
also	NULL
stimulated	NULL
CAT	NULL
production	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
,	NULL
but	NULL
to	NULL
lesser	NULL
degrees	NULL
than	NULL
LPS	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Our	NULL
ability	NULL
to	NULL
demonstrate	NULL
HIV-1-LTR	NULL
CAT	NULL
stimulation	NULL
by	NULL
PMA	NULL
and	NULL
PHA	NULL
in	NULL
THP-1	NULL
cells	NULL
is	NULL
at	NULL
variance	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
7	NULL
)	NULL
.	NULL

A	NULL
concentration	NULL
of	NULL
TNF-of	NULL
1,000	NULL
U/ml	NULL
,	NULL
as	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
resulted	NULL
in	NULL
the	NULL
greatest	NULL
level	NULL
of	NULL
stimulation	NULL
in	NULL
a	NULL
dose-response	NULL
curve	NULL
with	NULL
this	NULL
cytokine	NULL
.	NULL

Above	NULL
this	NULL
level	NULL
cytotoxicity	NULL
was	NULL
evident	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mock	NULL
transfections	NULL
consistently	NULL
gave	NULL
percent	NULL
conversion	NULL
levels	NULL
of	NULL
<	NULL
1	NULL
%	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
LPS	NULL
could	NULL
induce	NULL
CAT	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
HIV-1-LTR	NULL
CAT	NULL
plasmid	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
not	NULL
stimulated	NULL
by	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
although	NULL
PMA	NULL
and	NULL
PHA	NULL
,	NULL
as	NULL
previously	NULL
demonstrated	NULL
(	NULL
4	NULL
)	NULL
,	NULL
stimulated	NULL
CAT	NULL
activity	NULL
in	NULL
this	NULL
cell	NULL
35	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
)	NULL
.	NULL

TNF-	NULL
was	NULL
also	NULL
demonstrated	NULL
to	NULL
stimulate	NULL
the	NULL
HIV-1-LTR-directed	NULL
CAT	NULL
gene	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
LPS	NULL
might	NULL
stimulate	NULL
HIV-1-LTR	NULL
CAT	NULL
at	NULL
physiologically	NULL
significant	NULL
concentrations	NULL
,	NULL
various	NULL
amounts	NULL
of	NULL
LPS	NULL
were	NULL
added	NULL
to	NULL
transient	NULL
transfections	NULL
.	NULL

LPS	NULL
was	NULL
able	NULL
to	NULL
stimulate	NULL
HIV-1-LTR	NULL
CAT	NULL
in	NULL
U937	NULL
cells	NULL
to	NULL
a	NULL
significant	NULL
degree	NULL
at	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
10	NULL
pg/ml	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
not	NULL
evident	NULL
at	NULL
1	NULL
pg/ml	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Stimulation	NULL
decreased	NULL
over	NULL
the	NULL
range	NULL
of	NULL
LPS	NULL
concentrations	NULL
from	NULL
100	NULL
ng	NULL
to	NULL
10	NULL
pg/ml	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
HIV-A-LTR	NULL
were	NULL
necessary	NULL
for	NULL
LPS-induced	NULL
CAT	NULL
stimulation	NULL
,	NULL
an	NULL
HIV-1-LTR	NULL
CAT	NULL
construct	NULL
with	NULL
mutant	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
(	NULL
4	NULL
)	NULL
(	NULL
HIV-NF-	NULL
«	NULL
B	NULL
A	NULL
CAT	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
.	NULL

LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
when	NULL
added	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
led	NULL
to	NULL
no	NULL
significant	NULL
stimulation	NULL
in	NULL
CAT	NULL
activity	NULL
in	NULL
U937	NULL
or	NULL
THP-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
from	NULL
this	NULL
construct	NULL
was	NULL
also	NULL
not	NULL
stimulated	NULL
above	NULL
baseline	NULL
by	NULL
TNF-	NULL
or	NULL
PMA	NULL
and	NULL
PHA	NULL
treatment	NULL
in	NULL
the	NULL
U937	NULL
and	NULL
THP-1	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
regions	NULL
other	NULL
than	NULL
the	NULL
xB	NULL
sites	NULL
in	NULL
the	NULL
HIV-1-LTR	NULL
were	NULL
required	NULL
for	NULL
LPS-induced	NULL
CAT	NULL
stimulation	NULL
,	NULL
a	NULL
plasmid	NULL
(	NULL
J18	NULL
)	NULL
containing	NULL
two	NULL
KB	NULL
sites	NULL
from	NULL
the	NULL
x	NULL
enhancer	NULL
B	NULL
_	NULL
100	NULL
Plasmid	NULL
CS	NULL
HIV	NULL
CAT	NULL
Waa	NULL
HIV	NULL
NFB	NULL
CAT	NULL
>	NULL
90	NULL
HR	NULL
Fos	NULL
NFB	NULL
CAT	NULL
E	NULL
9	NULL
$	NULL
3	NULL
2l	NULL
_-	NULL
[	NULL
G	NULL
l	NULL
I	NULL
|	NULL
&	NULL
C	NULL
e	NULL
-*~=	NULL
|	NULL
1I	NULL
x..	NULL
|	NULL
Fak	NULL
J	NULL
LJ	NULL
22.0	NULL
__	NULL
Wh	NULL
PMA	NULL
,	NULL
PHA	NULL
TNFa	NULL
a	NULL
LPS	NULL
s	NULL
23	NULL
47	NULL
Figure	NULL
1	NULL
.	NULL

CAT	NULL
stimulation	NULL
in	NULL
transient	NULL
transfections	NULL
of	NULL
U937	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
U937	NULL
cells	NULL
,	NULL
(	NULL
B	NULL
)	NULL
THP-1	NULL
cells	NULL
,	NULL
(	NULL
C	NULL
)	NULL
Jurkat	NULL
cells	NULL
.	NULL

107	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
various	NULL
plasmids	NULL
and	NULL
treated	NULL
with	NULL
different	NULL
agents	NULL
at	NULL
24	NULL
h	NULL
(	NULL
PMA	NULL
50	NULL
ng/ml	NULL
and	NULL
PHA	NULL
2	NULL
ug/ml	NULL
,	NULL
1,000	NULL
U/ml	NULL
,	NULL
or	NULL
LPS	NULL
A	NULL
f	NULL
Plasmid	NULL
25t	NULL
(	NULL
GS	NULL
HIV	NULL
CAT	NULL
|	NULL
HIV	NULL
NFeBA	NULL
CAT	NULL
HR	NULL
Fos	NULL
NFB	NULL
CAT	NULL
15	NULL
§	NULL
§	NULL
10f	NULL
&	NULL
&	NULL
é	NULL
|	NULL
rviz	NULL
]	NULL
€	NULL
N	NULL
|	NULL
|	NULL
}	NULL
5	NULL
}	NULL
|	NULL
|	NULL
o	NULL
B	NULL
_	NULL
_	NULL
E	NULL
0	NULL
u	NULL
)	NULL
CLC	NULL
_	NULL
TREATMENT	NULL
:	NULL
=	NULL
LPS	NULL
-	NULL
PMA	NULL
,	NULL
PHA	NULL
-	NULL
TNF	NULL
-	NULL
LPS	NULL
LPS	NULL
FOLD	NULL
INCREASE	NULL
1	NULL
106	NULL
36	NULL
6	NULL
10	NULL
;	NULL
>	NULL
Plasmid	NULL
:	NULL
HIV	NULL
CAT	NULL
C	NULL
s	NULL
©	NULL
$	NULL
§	NULL
|	NULL
&	NULL
€	NULL
|	NULL
Bu	NULL
ol	NULL
ome	NULL
%	NULL
od	NULL
TREATMENT	NULL
LPS	NULL
.	NULL

PMA	NULL
,	NULL
PHA	NULL
FOLO	NULL
INCREASE	NULL
1	NULL
9	NULL
255	NULL
Pomerantz	NULL
et	NULL
al	NULL
.	NULL

10	NULL
ug/ml	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
harvested	NULL
for	NULL
CAT	NULL
assays	NULL
44	NULL
h	NULL
after	NULL
transfection	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
endotoxin	NULL
in	NULL
the	NULL
medium	NULL
and	NULL
the	NULL
FCS	NULL
was	NULL
0.3	NULL
and	NULL
1.4	NULL
endotoxin	NULL
units	NULL
(	NULL
EU	NULL
)	NULL
per	NULL
milliliter	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
level	NULL
of	NULL
endotoxin	NULL
in	NULL
the	NULL
TNF-	NULL
was	NULL
<	NULL
0.001	NULL
EU	NULL
per	NULL
unit	NULL
of	NULL
TNF-	NULL
.	NULL

The	NULL
percent	NULL
conversion	NULL
of	NULL
[	NULL
!	NULL

*CJchloramphenicol	NULL
was	NULL
measured	NULL
and	NULL
bar	NULL
graphs	NULL
illustrate	NULL
the	NULL
arithmetic	NULL
mean	NULL
of	NULL
between	NULL
two	NULL
and	NULL
six	NULL
separate	NULL
experiments	NULL
+	NULL
SEM	NULL
.	NULL

The	NULL
transfections	NULL
not	NULL
treated	NULL
with	NULL
any	NULL
agent	NULL
are	NULL
noted	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
graph	NULL
by	NULL
a	NULL
negative	NULL
sign	NULL
.	NULL

The	NULL
``	NULL
fold	NULL
increase	NULL
``	NULL
shown	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
HIV-CAT	NULL
transfections	NULL
represent	NULL
the	NULL
increased	NULL
conversion	NULL
of	NULL
[	NULL
!	NULL

``	NULL
C	NULL
]	NULL
chloramphenicol	NULL
compared	NULL
with	NULL
the	NULL
untreated	NULL
HIV-CAT	NULL
transfections	NULL
which	NULL
are	NULL
given	NULL
the	NULL
value	NULL
of	NULL
1	NULL
.	NULL

HIV-CAT	NULL
plasmid	NULL
is	NULL
a	NULL
HIV-1-LTR	NULL
linked	NULL
to	NULL
a	NULL
CAT	NULL
gene	NULL
.	NULL

The	NULL
HIV	NULL
NF-	NULL
«	NULL
B	NULL
A	NULL
CAT	NULL
plasmid	NULL
is	NULL
an	NULL
HIV-1-LTR	NULL
with	NULL
mutations	NULL
in	NULL
both	NULL
KB	NULL
sites	NULL
linked	NULL
to	NULL
a	NULL
CAT	NULL
gene	NULL
.	NULL

Fos	NULL
NF-	NULL
«	NULL
B	NULL
CAT	NULL
plasmid	NULL
(	NULL
J18	NULL
)	NULL
contains	NULL
two	NULL
B	NULL
sites	NULL
upstream	NULL
of	NULL
a	NULL
truncated	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL
'	NULL

PERCENT	NULL
CONVERSION	NULL
100	NULL
10	NULL
4	NULL
100	NULL
10	NULL
1	NULL
_	NULL
NaLPS	NULL
-	NULL
ng/m	NULL
!	NULL

A	NULL
<	NULL
--	NULL
-	NULL
pg/ml	NULL
'	NULL
Added	NULL
LPS	NULL
CONCENTRATION	NULL
Figure	NULL
2	NULL
.	NULL

Dose	NULL
response	NULL
of	NULL
HIV-CAT	NULL
stimulation	NULL
by	NULL
LPS	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

10	NULL
``	NULL
U937	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
HIV-CAT	NULL
plasmid	NULL
.	NULL

24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
various	NULL
amounts	NULL
of	NULL
LPS	NULL
were	NULL
added	NULL
to	NULL
give	NULL
differing	NULL
final	NULL
concentrations	NULL
of	NULL
LPS	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Cell	NULL
ly-sates	NULL
were	NULL
harvested	NULL
44	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Percent	NULL
conversions	NULL
of	NULL
[	NULL
!	NULL

*CJchloramphenicol	NULL
are	NULL
the	NULL
arithmetic	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
.	NULL

-piq/ml	NULL
upstream	NULL
of	NULL
a	NULL
truncated	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
a	NULL
CAT	NULL
gene	NULL
(	NULL
21	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
.	NULL

When	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
a	NULL
large	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
in	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
was	NULL
demonstrated	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
4	NULL
and	NULL
U937	NULL
1	NULL
2	NULL
3	NULL
4	NULL
=	NULL
§	NULL
PLASMID	NULL
:	NULL
'	NULL
--	NULL
--	NULL
--	NULL
-	NULL
HIV	NULL
CAT	NULL
--	NULL
--	NULL
-	NULL
TREATMENT	NULL
:	NULL
=-	NULL
LPS	NULL
-	NULL
LPS+	NULL
TNF	NULL
TNF+	NULL
Anti-TNFa	NULL
_	NULL
Anti-TNFa	NULL
Ab	NULL
Ab	NULL
%	NULL
CONVERSION	NULL
:	NULL
1A	NULL
414.5	NULL
11.14	NULL
6.14	NULL
2.4	NULL
0.13	NULL
#	NULL
10	NULL
#	NULL
1.1	NULL
*+06	NULL
+0.23	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Anti	NULL
antibody	NULL
treatments	NULL
of	NULL
HIV-CAT	NULL
transfections	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
HIV-CAT	NULL
plasmid	NULL
and	NULL
treated	NULL
with	NULL
LPS	NULL
or	NULL
TNFa	NULL
,	NULL
with	NULL
or	NULL
without	NULL
anti-TNFa	NULL
antibody	NULL
,	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

20	NULL
pul	NULL
of	NULL
anti'TNF-	NULL
@	NULL
antibody	NULL
,	NULL
which	NULL
neutralizes	NULL
2	NULL
x	NULL
10+	NULL
U	NULL
of	NULL
TNF-	NULL
,	NULL
were	NULL
added	NULL
to	NULL
appropriate	NULL
transfections	NULL
.	NULL

(	NULL
Lane	NULL
1	NULL
)	NULL
No	NULL
treatment	NULL
,	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
LPS	NULL
+	NULL
anti	NULL
TNF-	NULL
antibody	NULL
,	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
TNF-	NULL
(	NULL
1,000	NULL
U/ml	NULL
)	NULL
,	NULL
and	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
TNF-	NULL
+	NULL
antiTNF-	NULL
antibody	NULL
.	NULL

The	NULL
percent	NULL
conversions	NULL
of	NULL
[	NULL
!	NULL

*C	NULL
]	NULL
chloramphenicol	NULL
are	NULL
the	NULL
arithmetic	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
.	NULL

The	NULL
autoradiograph	NULL
shown	NULL
is	NULL
a	NULL
repre-	NULL
sentative	NULL
example	NULL
of	NULL
these	NULL
experiments	NULL
.	NULL

B	NULL
)	NULL
.	NULL

A	NULL
plasmid	NULL
lacking	NULL
the	NULL
«	NULL
B	NULL
sites	NULL
but	NULL
retaining	NULL
the	NULL
c-fos	NULL
promoter	NULL
linked	NULL
to	NULL
a	NULL
CAT	NULL
gene	NULL
(	NULL
21	NULL
)	NULL
was	NULL
not	NULL
stimulated	NULL
by	NULL
LPS	NULL
in	NULL
either	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Transfections	NULL
of	NULL
the	NULL
HIV-NF-	NULL
«	NULL
B	NULL
A	NULL
CAT	NULL
and	NULL
J18	NULL
plasmids	NULL
indicate	NULL
that	NULL
the	NULL
LPS	NULL
stimulation	NULL
of	NULL
the	NULL
HIV-1-LTR	NULL
CAT	NULL
in	NULL
the	NULL
U937	NULL
and	NULL
THP-1	NULL
cell	NULL
lines	NULL
is	NULL
based	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
NF-KB	NULL
and	NULL
its	NULL
binding	NULL
to	NULL
KB	NULL
enhancer	NULL
motifs	NULL
in	NULL
the	NULL
LTR	NULL
.	NULL

To	NULL
ascertain	NULL
if	NULL
the	NULL
LPS-induced	NULL
CAT	NULL
stimulation	NULL
was	NULL
caused	NULL
by	NULL
TNF-	NULL
@	NULL
released	NULL
from	NULL
cells	NULL
,	NULL
HIV-1-LTR	NULL
CAT	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
then	NULL
either	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
plus	NULL
or	NULL
minus	NULL
anti-TNF-a	NULL
antibody	NULL
,	NULL
TNF-a	NULL
(	NULL
1,000	NULL
U/ml	NULL
)	NULL
plus	NULL
or	NULL
minus	NULL
anti-'TNF-a	NULL
antibody	NULL
,	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Anti'TNF-x	NULL
antibody	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
LPS-induced	NULL
stimulation	NULL
of	NULL
HIV-1-LTR	NULL
CAT	NULL
but	NULL
reduced	NULL
by	NULL
~86	NULL
%	NULL
the	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
induced	NULL
by	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Anti'TNF-a	NULL
@	NULL
antibody	NULL
was	NULL
also	NULL
unable	NULL
to	NULL
block	NULL
LPS-induced	NULL
CAT	NULL
stimulation	NULL
in	NULL
the	NULL
THP-1	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LPS	NULL
Induces	NULL
an	NULL
Activity	NULL
in	NULL
Monocyte/Macrophage-like	NULL
Cell	NULL
Lines	NULL
that	NULL
Binds	NULL
to	NULL
«	NULL
B	NULL
sites	NULL
on	NULL
EMSA	NULL
.	NULL

-	NULL
Cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
brief	NULL
protocol	NULL
(	NULL
25	NULL
)	NULL
,	NULL
rather	NULL
than	NULL
the	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
,	NULL
for	NULL
EMSA	NULL
.	NULL

This	NULL
method	NULL
gave	NULL
more	NULL
background	NULL
bands	NULL
but	NULL
allowed	NULL
the	NULL
use	NULL
of	NULL
small	NULL
amounts	NULL
of	NULL
cells	NULL
and	NULL
minimized	NULL
proteolysis	NULL
common	NULL
in	NULL
the	NULL
manipulation	NULL
of	NULL
monocyte/	NULL
macrophage-like	NULL
cell	NULL
lines	NULL
.	NULL

A	NULL
binding	NULL
activity	NULL
,	NULL
indistinguishable	NULL
from	NULL
NF-KB	NULL
,	NULL
was	NULL
found	NULL
in	NULL
extracts	NULL
of	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
treated	NULL
with	NULL
LPS	NULL
but	NULL
not	NULL
Jurkat	NULL
cells	NULL
.	NULL

This	NULL
binding	NULL
activity	NULL
was	NULL
induced	NULL
after	NULL
only	NULL
30	NULL
min	NULL
of	NULL
LPS	NULL
treatment	NULL
of	NULL
U937	NULL
cells	NULL
and	NULL
increased	NULL
over	NULL
treatment	NULL
periods	NULL
up	NULL
to	NULL
2	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Prolonged	NULL
treatment	NULL
with	NULL
LPS	NULL
showed	NULL
persistent	NULL
but	NULL
reduced	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
THP-1	NULL
cells	NULL
stimulated	NULL
with	NULL
LPS	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
but	NULL
contrary	NULL
to	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
7	NULL
)	NULL
,	NULL
little	NULL
of	NULL
this	NULL
activity	NULL
was	NULL
found	NULL
in	NULL
our	NULL
unstimulated	NULL
THP-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

This	NULL
LPS-inducible	NULL
complex	NULL
comigrated	NULL
with	NULL
a	NULL
PMA	NULL
plus	NULL
PHA-inducible	NULL
complex	NULL
in	NULL
U937	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
10	NULL
,	NULL
17	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Peak	NULL
levels	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
were	NULL
induced	NULL
by	NULL
PMA/PHA	NULL
in	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
with	NULL
overnight	NULL
treatment	NULL
,	NULL
while	NULL
PMA/PHA	NULL
treatment	NULL
gave	NULL
its	NULL
greatest	NULL
effect	NULL
in	NULL
Jurkat	NULL
cells	NULL
after	NULL
2	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LPS	NULL
is	NULL
a	NULL
much	NULL
more	NULL
potent	NULL
stimulus	NULL
for	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
in	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
than	NULL
PMA	NULL
plus	NULL
PHA	NULL
.	NULL

LPS	NULL
was	NULL
unable	NULL
to	NULL
stimulate	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lane	NULL
20	NULL
)	NULL
.	NULL

The	NULL
LPS-inducible	NULL
complex	NULL
was	NULL
specifically	NULL
competed	NULL
away	NULL
by	NULL
.	NULL

an	NULL
unlabeled	NULL
fragment	NULL
composed	NULL
of	NULL
both	NULL
«	NULL
B	NULL
sites	NULL
from	NULL
the	NULL
HIV-1-LT	NULL
R	NULL
in	NULL
reactions	NULL
with	NULL
cellular	NULL
extracts	NULL
from	NULL
both	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
6-8	NULL
and	NULL
13-15	NULL
)	NULL
.	NULL

An	NULL
unlabeled	NULL
fragment	NULL
with	NULL
mutations	NULL
in	NULL
the	NULL
«	NULL
B	NULL
sites	NULL
of	NULL
the	NULL
HIV-1-LTR	NULL
was	NULL
unable	NULL
to	NULL
compete	NULL
with	NULL
this	NULL
binding	NULL
activity	NULL
from	NULL
LPS-stimulated	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
16	NULL
)	NULL
.	NULL

The	NULL
unlabeled	NULL
competitor	NULL
fragment	NULL
effectively	NULL
competed	NULL
with	NULL
binding	NULL
activity	NULL
found	NULL
in	NULL
PMA	NULL
plus	NULL
PHA-treated	NULL
Jurkat	NULL
cell	NULL
extracts	NULL
,	NULL
while	NULL
the	NULL
mutant	NULL
unlabeled	NULL
fragment	NULL
showed	NULL
256	NULL
Lipopolysaccharide	NULL
and	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
r	NULL
U937	NULL
THP1	NULL
--	NULL
Jurkat	NULL
--	NULL
Figure	NULL
4	NULL
.	NULL

Electrophoretic	NULL
mobil-a	NULL
a	NULL
a	NULL
ity	NULL
shift	NULL
assays	NULL
of	NULL
U937	NULL
,	NULL
THP-1	NULL
,	NULL
g	NULL
g	NULL
§	NULL
and	NULL
Jurkat	NULL
cells	NULL
.	NULL

5	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
in	NULL
.	NULL

s	NULL
a	NULL
E	NULL
a	NULL
a	NULL
E	NULL
a	NULL
=	NULL
50	NULL
ml	NULL
of	NULL
medium	NULL
were	NULL
treated	NULL
e	NULL
§	NULL
§	NULL
3	NULL
2	NULL
§	NULL
§	NULL
3	NULL
€	NULL
S	NULL
with	NULL
various	NULL
agents	NULL
over	NULL
differing	NULL
8	NULL
0	NULL
o	NULL
o	NULL
8	NULL
o	NULL
o	NULL
a	NULL
>	NULL
&	NULL
time	NULL
periods	NULL
.	NULL

Cellular	NULL
extracts	NULL
2	NULL
05	NULL
o	NULL
6	NULL
2	NULL
5	NULL
6	NULL
o	NULL
6	NULL
5	NULL
were	NULL
prepared	NULL
and	NULL
EMSAs	NULL
per-C	NULL
_	NULL
3	NULL
,	NULL
2	NULL
+	NULL
2	NULL
C	NULL
_	NULL
2	NULL
3+	NULL
2	NULL
z	NULL
TT	NULL
formed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
€	NULL
t	NULL
£	NULL
ppp	NULL
Ef	NULL
o	NULL
:	NULL
oi	NULL
if	NULL
and	NULL
Methods	NULL
m	NULL
-	NULL
<	NULL
w	NULL
8	NULL
w	NULL
w	NULL
aw	NULL
w	NULL
&	NULL
a	NULL
a	NULL
ou	NULL
ou	NULL
o	NULL
+	NULL
&	NULL
+0	NULL
+	NULL
(	NULL
Lane	NULL
1	NULL
)	NULL
U937	NULL
,	NULL
no	NULL
treatment	NULL
w	NULL
a	NULL
a	NULL
a	NULL
ao	NULL
ao	NULL
a	NULL
ga	NULL
o	NULL
a	NULL
o	NULL
a	NULL
<	NULL
o	NULL
g	NULL
I	NULL
ted	NULL
ti	NULL
-l	NULL
sign	NULL
)	NULL
.	NULL

meamenr	NULL
v	NULL
%	NULL
8	NULL
%	NULL
%	NULL
%	NULL
%	NULL
§	NULL
§	NULL
B	NULL
.	NULL

€	NULL
§5	NULL
5	NULL
§	NULL
GB	NULL
.	NULL

|	NULL
€	NULL
f	NULL
f	NULL
(	NULL
eames	NULL
231	NULL
6997	NULL
0	NULL
tie	NULL
(	NULL
10	NULL
ug/	NULL
ml	NULL
)	NULL
over	NULL
various	NULL
stimulation	NULL
time	NULL
periods	NULL
.	NULL

(	NULL
Lanes	NULL
6-8	NULL
)	NULL
U937	NULL
+	NULL
LPS	NULL
and	NULL
differing	NULL
amounts	NULL
of	NULL
unlabeled	NULL
&	NULL
competitor	NULL
(	NULL
comp	NULL
)	NULL
.	NULL

(	NULL
Lane	NULL
9	NULL
)	NULL
U937	NULL
>	NULL
.	NULL

WA	NULL
C	NULL
+	NULL
LPS	NULL
and	NULL
20	NULL
ng	NULL
of	NULL
mutant	NULL
unla-	NULL
“	NULL
f	NULL
&	NULL
beled	NULL
competitor	NULL
.	NULL

(	NULL
Lane	NULL
10	NULL
)	NULL
U937	NULL
ad	NULL
s	NULL
_	NULL
``	NULL
I	NULL
+	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
plus	NULL
PHA	NULL
(	NULL
2	NULL
1o	NULL
2	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
ug/ml	NULL
)	NULL
overnight	NULL
stimulation	NULL
.	NULL

(	NULL
Lane	NULL
11	NULL
)	NULL
THP-1	NULL
,	NULL
no	NULL
treatment	NULL
.	NULL

(	NULL
Lane	NULL
12	NULL
)	NULL
THP1	NULL
+	NULL
LPS	NULL
,	NULL
2	NULL
h	NULL
stimulation	NULL
.	NULL

(	NULL
Lane	NULL
13-15	NULL
)	NULL
THP-1	NULL
+	NULL
LPS	NULL
and	NULL
differing	NULL
amounts	NULL
of	NULL
unlabeled	NULL
competitor	NULL
.	NULL

(	NULL
Lane	NULL
16	NULL
)	NULL
THP-1	NULL
+	NULL
LPS	NULL
and	NULL
20	NULL
ng	NULL
of	NULL
mutant	NULL
unlabeled	NULL
competitor	NULL
.	NULL

(	NULL
Lane	NULL
17	NULL
)	NULL
THP-A1	NULL
+	NULL
PMA	NULL
and	NULL
PHA	NULL
overnight	NULL
stimulation	NULL
.	NULL

(	NULL
Lane	NULL
18	NULL
)	NULL
Jurkat	NULL
,	NULL
no	NULL
treatment	NULL
.	NULL

(	NULL
Lane	NULL
19	NULL
)	NULL
Jurkat	NULL
+	NULL
PMA	NULL
and	NULL
PHA	NULL
,	NULL
2	NULL
h	NULL
stimulation	NULL
.	NULL

(	NULL
Lane	NULL
20	NULL
)	NULL
Jurkat	NULL
+	NULL
LPS	NULL
,	NULL
2	NULL
h	NULL
stimulation	NULL
.	NULL

(	NULL
Lane	NULL
21	NULL
)	NULL
19	NULL
20	NULL
21	NULL
22	NULL
Jurkat	NULL
+	NULL
PMA	NULL
and	NULL
PHA	NULL
20	NULL
ng	NULL
competitor	NULL
.	NULL

(	NULL
Lane	NULL
22	NULL
)	NULL
Jurkat	NULL
+	NULL
PMA	NULL
and	NULL
PHA	NULL
and	NULL
20	NULL
ng	NULL
mutant	NULL
competitor	NULL
.	NULL

The	NULL
autoradiograph	NULL
illustrated	NULL
was	NULL
slightly	NULL
overexposed	NULL
to	NULL
demonstrate	NULL
changes	NULL
in	NULL
the	NULL
NF-KB	NULL
band	NULL
in	NULL
lanes	NULL
where	NULL
various	NULL
amounts	NULL
of	NULL
unlabeled	NULL
competitor	NULL
were	NULL
added	NULL
.	NULL

(	NULL
Filled	NULL
arrowheads	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
band	NULL
;	NULL
(	NULL
open	NULL
arrowheads	NULL
)	NULL
unbound	NULL
probe	NULL
.	NULL

no	NULL
competition	NULL
with	NULL
this	NULL
binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
21	NULL
and	NULL
22	NULL
)	NULL
.	NULL

The	NULL
above	NULL
data	NULL
demonstrate	NULL
that	NULL
LPS	NULL
induces	NULL
a	NULL
binding	NULL
activity	NULL
indistinguishable	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
.	NULL

Stimulation	NULL
of	NULL
HIVA	NULL
Production	NULL
by	NULL
LPS	NULL
in	NULL
U1	NULL
Cells	NULL
Pretreated	NULL
with	NULL
GM-CSF	NULL
.	NULL

The	NULL
U1	NULL
cell	NULL
line	NULL
is	NULL
a	NULL
subclone	NULL
of	NULL
HIV-1-infected	NULL
U937	NULL
cells	NULL
which	NULL
constitutively	NULL
produce	NULL
very	NULL
low	NULL
amounts	NULL
of	NULL
virus	NULL
.	NULL

These	NULL
cells	NULL
can	NULL
be	NULL
stimulated	NULL
to	NULL
produce	NULL
much	NULL
greater	NULL
amounts	NULL
of	NULL
HIV-1	NULL
by	NULL
treatment	NULL
with	NULL
TNF-	NULL
«	NULL
x	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
7	NULL
,	NULL
9	NULL
)	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
reproduce	NULL
these	NULL
findings	NULL
.	NULL

We	NULL
noted	NULL
a	NULL
320-and	NULL
27-fold	NULL
increase	NULL
in	NULL
p24	NULL
antigen	NULL
levels	NULL
over	NULL
baseline	NULL
with	NULL
TNF-	NULL
«	NULL
and	NULL
GM-CSF	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

PMA	NULL
plus	NULL
PHA	NULL
induced	NULL
p24	NULL
antigen	NULL
levels	NULL
to	NULL
>	NULL
100	NULL
ng/ml	NULL
by	NULL
day	NULL
3	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LPS	NULL
alone	NULL
,	NULL
however	NULL
,	NULL
failed	NULL
to	NULL
yield	NULL
a	NULL
consistent	NULL
increase	NULL
in	NULL
p24	NULL
antigen	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
)	NULL
.	NULL

There	NULL
was	NULL
<	NULL
0.2	NULL
ng/ml	NULL
of	NULL
p24	NULL
antigen	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
unstimulated	NULL
U1	NULL
cells	NULL
by	NULL
the	NULL
third	NULL
day	NULL
in	NULL
culture	NULL
.	NULL

Reasoning	NULL
that	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
might	NULL
be	NULL
a	NULL
relatively	NULL
immature	NULL
subclone	NULL
of	NULL
U937	NULL
cells	NULL
,	NULL
we	NULL
attempted	NULL
to	NULL
differentiate	NULL
this	NULL
cell	NULL
line	NULL
using	NULL
GM-CSF	NULL
before	NULL
treatment	NULL
with	NULL
LPS	NULL
.	NULL

After	NULL
treatment	NULL
for	NULL
24	NULL
h	NULL
with	NULL
GM-CSF	NULL
,	NULL
LPS	NULL
led	NULL
to	NULL
a	NULL
200-fold	NULL
increase	NULL
in	NULL
p24	NULL
antigen	NULL
levels	NULL
in	NULL
the	NULL
supernatant	NULL
compared	NULL
with	NULL
untreated	NULL
cultures	NULL
,	NULL
and	NULL
a	NULL
7.4-fold	NULL
increase	NULL
compared	NULL
with	NULL
cultures	NULL
treated	NULL
solely	NULL
with	NULL
GM-CSF	NULL
by	NULL
day	NULL
3	NULL
after	NULL
LPS	NULL
treat	NULL
257	NULL
Pomerantz	NULL
et	NULL
al	NULL
.	NULL

ment	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

We	NULL
were	NULL
further	NULL
able	NULL
to	NULL
demonstrate	NULL
that	NULL
after	NULL
GM-CSF	NULL
pretreatment	NULL
,	NULL
HIV-1	NULL
production	NULL
could	NULL
be	NULL
further	NULL
augmented	NULL
in	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
with	NULL
concentrations	NULL
of	NULL
LPS	NULL
as	NULL
low	NULL
as	NULL
100	NULL
pg/ml	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
stimulatory	NULL
effects	NULL
on	NULL
HIV-1	NULL
production	NULL
in	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
resulted	NULL
in	NULL
increased	NULL
levels	NULL
of	NULL
HIV-1-specific	NULL
RNA	NULL
(	NULL
Pomerantz	NULL
,	NULL
R.J.	NULL
,	NULL
D.	NULL
Trono	NULL
,	NULL
M.	NULL
Feinberg	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
,	NULL
manuscript	NULL
submitted	NULL
for	NULL
publication	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
LPS-mediated	NULL
stimulation	NULL
of	NULL
HIV-1	NULL
in	NULL
UA	NULL
cells	NULL
was	NULL
due	NULL
to	NULL
the	NULL
release	NULL
of	NULL
TNF-	NULL
from	NULL
the	NULL
GM-CSF-treated	NULL
U1	NULL
cells	NULL
,	NULL
we	NULL
added	NULL
anti-TNF-	NULL
@	NULL
neutralizing	NULL
antibody	NULL
to	NULL
cultures	NULL
treated	NULL
with	NULL
GM-CSF	NULL
plus	NULL
LPS	NULL
.	NULL

This	NULL
antibody	NULL
had	NULL
a	NULL
minimal	NULL
effect	NULL
on	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
production	NULL
in	NULL
GM-CSF	NULL
pretreated	NULL
cells	NULL
to	NULL
which	NULL
LPS	NULL
was	NULL
added	NULL
,	NULL
although	NULL
it	NULL
was	NULL
able	NULL
to	NULL
totally	NULL
ablate	NULL
the	NULL
stimulation	NULL
of	NULL
virus	NULL
production	NULL
induced	NULL
by	NULL
1,000	NULL
U/ml	NULL
of	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

A	NULL
chronically	NULL
HIV-1-infected	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
ACH-2	NULL
,	NULL
which	NULL
constitutively	NULL
produces	NULL
small	NULL
amounts	NULL
of	NULL
virus	NULL
,	NULL
was	NULL
also	NULL
treated	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
agents	NULL
.	NULL

Although	NULL
TNF-	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
viral	NULL
production	NULL
,	NULL
LPS	NULL
alone	NULL
,	NULL
GM-CSF	NULL
alone	NULL
,	NULL
and	NULL
GM-CSF	NULL
plus	NULL
LPS	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
viral	NULL
replication	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
C	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
NF-KB-like	NULL
Binding	NULL
Activity	NULL
in	NULL
U1	NULL
Cells	NULL
by	NULL
LPS	NULL
after	NULL
Pretreatment	NULL
with	NULL
GM-CSF	NULL
.	NULL

To	NULL
demonstrate	NULL
that	NULL
the	NULL
LPS-mediated	NULL
increase	NULL
in	NULL
HIV-1	NULL
production	NULL
in	NULL
U1	NULL
cells	NULL
pretreated	NULL
with	NULL
GM-CSF	NULL
was	NULL
correlated	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
40	NULL
A	NULL
©	NULL
No	NULL
Treatment	NULL
©	NULL
TNFa	NULL
30	NULL
}	NULL
V	NULL
LPS	NULL
O	NULL
TNFa+Anti-TNFa	NULL
Antibody	NULL
p24	NULL
ANTIGEN	NULL
(	NULL
ng/ml	NULL
)	NULL
‘	NULL
0	NULL
1	NULL
1	NULL
1	NULL
Day	NULL
1	NULL
Day	NULL
2	NULL
Day	NULL
3	NULL
25	NULL
O	NULL
No	NULL
Treatment	NULL
&	NULL
GMCSF	NULL
<	NULL
op|-	NULL
A	NULL
GMCSF+LPS	NULL
€	NULL
V|	NULL
-	NULL
a	NULL
GMCSF+LPS+Anti-TNFa	NULL
Antibody	NULL
&	NULL
15	NULL
ad	NULL
u	NULL
G	NULL
R	NULL
S	NULL
10	NULL
<	NULL
&	NULL
Yos	NULL
0	NULL
an	NULL
)	NULL
lo	NULL
o	NULL
Day	NULL
1	NULL
Day	NULL
2	NULL
Day	NULL
3	NULL
80	NULL
C	NULL
©	NULL
No	NULL
Treatment	NULL
v	NULL
LPS	NULL
60|-	NULL
e	NULL
cmcsF	NULL
A	NULL
GMCSF+LPS	NULL
*	NULL
TNFa	NULL
Q	NULL
40	NULL
“	NULL
€	NULL
t	NULL
&	NULL
20	NULL
:	NULL
—	NULL
R	NULL
§	NULL
s.	NULL
x	NULL
C	NULL
21	NULL
o	NULL
1	NULL
1	NULL
1	NULL
Day	NULL
1	NULL
Day	NULL
2	NULL
Day	NULL
3	NULL
Figure	NULL
5	NULL
.	NULL

Production	NULL
of	NULL
HIV-1	NULL
from	NULL
the	NULL
U1	NULL
and	NULL
ACH-2	NULL
cell	NULL
lines	NULL
.	NULL

(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
U1	NULL
cells	NULL
,	NULL
(	NULL
C	NULL
)	NULL
ACH-2	NULL
cells	NULL
.	NULL

5	NULL
x	NULL
105	NULL
cells	NULL
were	NULL
placed	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
medium	NULL
in	NULL
24-well	NULL
plates	NULL
.	NULL

Different	NULL
agents	NULL
were	NULL
added	NULL
and	NULL
p24	NULL
antigen	NULL
levels	NULL
in	NULL
the	NULL
supernatants	NULL
were	NULL
determined	NULL
daily	NULL
for	NULL
3	NULL
d.	NULL
The	NULL
treatment	NULL
regimens	NULL
included	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
with	NULL
or	NULL
without	NULL
cellular	NULL
extracts	NULL
were	NULL
made	NULL
after	NULL
a	NULL
variety	NULL
of	NULL
treatment	NULL
protocols	NULL
and	NULL
the	NULL
binding	NULL
reactions	NULL
to	NULL
a	NULL
labeled	NULL
probe	NULL
with	NULL
2	NULL
«	NULL
B	NULL
sites	NULL
were	NULL
studied	NULL
by	NULL
EMSA	NULL
.	NULL

LPS	NULL
alone	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
in	NULL
U1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-like	NULL
activity	NULL
was	NULL
not	NULL
stimulated	NULL
by	NULL
LPS	NULL
alone	NULL
in	NULL
U1	NULL
cells	NULL
after	NULL
1	NULL
,	NULL
2	NULL
,	NULL
6	NULL
,	NULL
24	NULL
,	NULL
and	NULL
36	NULL
h	NULL
of	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
(	NULL
7	NULL
)	NULL
,	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
was	NULL
induced	NULL
in	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
PMA	NULL
and	NULL
PHA	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

As	NULL
reported	NULL
for	NULL
other	NULL
cell	NULL
lines	NULL
(	NULL
6	NULL
)	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
for	NULL
48	NULL
h	NULL
with	NULL
GM-CSF	NULL
did	NULL
not	NULL
induce	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

GM-CSF	NULL
did	NULL
not	NULL
induce	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
in	NULL
U1	NULL
cells	NULL
when	NULL
treated	NULL
for	NULL
time	NULL
periods	NULL
of	NULL
between	NULL
2	NULL
and	NULL
36	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

LPS	NULL
,	NULL
though	NULL
,	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
a	NULL
small	NULL
quantity	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
after	NULL
the	NULL
U1	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
GM-CSF	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

LPS	NULL
induced	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
in	NULL
GM-CSF	NULL
pretreated	NULL
U1	NULL
cells	NULL
only	NULL
if	NULL
added	NULL
to	NULL
the	NULL
medium	NULL
for	NULL
24	NULL
h	NULL
or	NULL
longer	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
comigrated	NULL
with	NULL
a	NULL
band	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
PHA	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
was	NULL
specifically	NULL
competed	NULL
away	NULL
with	NULL
an	NULL
unlabeled	NULL
DNA	NULL
fragment	NULL
with	NULL
two	NULL
«	NULL
B	NULL
sites	NULL
from	NULL
the	NULL
HIV-1-LTR	NULL
but	NULL
not	NULL
a	NULL
fragment	NULL
with	NULL
mutations	NULL
in	NULL
these	NULL
KB	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

This	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
,	NULL
therefore	NULL
,	NULL
indistinguishable	NULL
from	NULL
NF-KB	NULL
.	NULL

In	NULL
multiple	NULL
experiments	NULL
,	NULL
only	NULL
relatively	NULL
small	NULL
quantities	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
were	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
PHA	NULL
or	NULL
GMCSF	NULL
plus	NULL
LPS	NULL
in	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
compared	NULL
with	NULL
levels	NULL
induced	NULL
in	NULL
uncloned	NULL
and	NULL
uninfected	NULL
U937	NULL
cells	NULL
.	NULL

To	NULL
further	NULL
demonstrate	NULL
that	NULL
NF-KB	NULL
was	NULL
activated	NULL
by	NULL
PMA	NULL
plus	NULL
PHA	NULL
and	NULL
GM-CSF	NULL
plus	NULL
LPS	NULL
in	NULL
U1	NULL
cells	NULL
,	NULL
these	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
Fos	NULL
NF-KB	NULL
CAT	NULL
(	NULL
J18	NULL
)	NULL
plasmid	NULL
.	NULL

Treatment	NULL
of	NULL
these	NULL
treatment	NULL
transfections	NULL
with	NULL
PMA	NULL
plus	NULL
PHA	NULL
or	NULL
GM-CSF	NULL
plus	NULL
LPS	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
stimulation	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

Treatment	NULL
with	NULL
GM-CSF	NULL
alone	NULL
or	NULL
LPS	NULL
alone	NULL
did	NULL
not	NULL
stimulate	NULL
CAT	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Discussion	NULL
We	NULL
have	NULL
demonstrated	NULL
here	NULL
that	NULL
LPS	NULL
potently	NULL
activates	NULL
the	NULL
HIV-1-LTR	NULL
in	NULL
monocyte/macrophage-like	NULL
cell	NULL
lines	NULL
but	NULL
not	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
line	NULL
.	NULL

The	NULL
LPS	NULL
effect	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

LPS	NULL
increased	NULL
HIV-1	NULL
production	NULL
from	NULL
a	NULL
cloned	NULL
monocyte/macrophage-like	NULL
cell	NULL
line	NULL
which	NULL
was	NULL
pretreated	NULL
with	NULL
GM-CSF	NULL
.	NULL

These	NULL
LPS	NULL
effects	NULL
were	NULL
demonstrated	NULL
at	NULL
picogram	NULL
per	NULL
milliliter	NULL
concentrations	NULL
.	NULL

LPS	NULL
,	NULL
which	NULL
is	NULL
a	NULL
major	NULL
constituent	NULL
of	NULL
the	NULL
cell	NULL
walls	NULL
of	NULL
gram	NULL
negative	NULL
bacteria	NULL
,	NULL
has	NULL
a	NULL
plethora	NULL
of	NULL
effects	NULL
on	NULL
a	NULL
variety	NULL
of	NULL
cells	NULL
.	NULL

The	NULL
release	NULL
of	NULL
TNF-a	NULL
from	NULL
monocyte/macrophages	NULL
by	NULL
LPS	NULL
anti-T	NULL
NF-	NULL
antibody	NULL
(	NULL
4	NULL
pl	NULL
)	NULL
,	NULL
TNF-a	NULL
(	NULL
1,000	NULL
U/ml	NULL
)	NULL
with	NULL
or	NULL
without	NULL
anti-TNF-	NULL
antibody	NULL
,	NULL
GM-CSF	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
alone	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
followed	NULL
by	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

Certain	NULL
cultures	NULL
were	NULL
left	NULL
untreated	NULL
.	NULL

The	NULL
level	NULL
of	NULL
endotoxin	NULL
in	NULL
the	NULL
GM-CSF	NULL
was	NULL
<	NULL
0.001	NULL
EU	NULL
per	NULL
unit	NULL
of	NULL
GM-CSF	NULL
.	NULL

Data	NULL
points	NULL
represent	NULL
the	NULL
arithmetic	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
two	NULL
to	NULL
three	NULL
separate	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

258	NULL
Lipopolysaccharide	NULL
and	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
28	NULL
Day	NULL
3	NULL
24	NULL
}	NULL
I	NULL
in	NULL
.	NULL
)	NULL

r	NULL
'	NULL
I	NULL
“	NULL
i	NULL
‘	NULL
[	NULL
8	NULL
]	NULL
|	NULL
I	NULL
ma	NULL
[	NULL
I	NULL
|	NULL
‘	NULL
(	NULL
p	NULL
E	NULL
|	NULL
|	NULL
i	NULL
16	NULL
:	NULL
|	NULL
|	NULL
‘	NULL
y	NULL
|	NULL
|	NULL
:	NULL
|	NULL
|	NULL
o	NULL
J	NULL
|	NULL
(	NULL
O	NULL
E	NULL
:	NULL
12	NULL
)	NULL
i	NULL
|	NULL
|	NULL
_x	NULL
&	NULL
|	NULL
|	NULL
|	NULL
8	NULL
|	NULL
|	NULL
8	NULL
|	NULL
|	NULL
|	NULL
|	NULL
a	NULL
a	NULL
.	NULL

|	NULL
|	NULL
|	NULL
f	NULL
t	NULL
|I	NULL
|	NULL
r—Le	NULL
|	NULL
|	NULL
|	NULL
|	NULL
tA	NULL
|	NULL
l	NULL
0	NULL
k_	NULL
4	NULL
k_	NULL
*	NULL
*	NULL
10	NULL
1	NULL
100	NULL
|	NULL
100	NULL
10	NULL
__	NULL
GMCSF	NULL
No	NULL
pg/ml	NULL
-	NULL
pg/ml	NULL
-	NULL
ng/ml	NULL
-	NULL
ng/ml	NULL
_	NULL
pg/ml	NULL
_	NULL
pg/ml	NULL
_	NULL
Alone	NULL
Treatment	NULL
LPS	NULL
CONCENTRATION	NULL
Figure	NULL
6	NULL
.	NULL

-	NULL
Dose	NULL
response	NULL
of	NULL
HIV-1	NULL
production	NULL
in	NULL
GM-CSF	NULL
pretreated	NULL
U1	NULL
cells	NULL
by	NULL
LPS	NULL
.	NULL

Various	NULL
amounts	NULL
of	NULL
LPS	NULL
were	NULL
added	NULL
to	NULL
U1	NULL
cells	NULL
pretreated	NULL
with	NULL
GM-CSF	NULL
(	NULL
500	NULL
U/ml	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h.	NULL
p24	NULL
antigen	NULL
levels	NULL
were	NULL
measured	NULL
from	NULL
these	NULL
supernatants	NULL
on	NULL
the	NULL
third	NULL
day	NULL
after	NULL
LPS	NULL
was	NULL
added	NULL
.	NULL

Each	NULL
bar	NULL
is	NULL
the	NULL
arithmetic	NULL
mean	NULL
+	NULL
SEM	NULL
of	NULL
two	NULL
experiments	NULL
performed	NULL
in	NULL
duplicate	NULL
.	NULL

leads	NULL
to	NULL
many	NULL
but	NULL
not	NULL
all	NULL
the	NULL
pathophysiologic	NULL
effects	NULL
noted	NULL
during	NULL
endotoxemia	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

LPS	NULL
activates	NULL
macrophages	NULL
and	NULL
induces	NULL
Interleukin	NULL
I	NULL
,	NULL
Interleukin	NULL
6	NULL
and	NULL
Interferon	NULL
y	NULL
production	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

LPS	NULL
is	NULL
also	NULL
a	NULL
murine	NULL
B	NULL
lymphocyte	NULL
mitogen	NULL
and	NULL
will	NULL
activate	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
induce	NULL
NF-KB	NULL
in	NULL
pre-B	NULL
cells	NULL
although	NULL
it	NULL
has	NULL
little	NULL
effect	NULL
on	NULL
T	NULL
lymphocytes	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
LPS-induced	NULL
effects	NULL
are	NULL
seen	NULL
with	NULL
nanogram	NULL
or	NULL
picogram	NULL
per	NULL
milliliter	NULL
concentrations	NULL
(	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

LPS	NULL
may	NULL
not	NULL
activate	NULL
NF-KB	NULL
in	NULL
T	NULL
cells	NULL
for	NULL
lack	NULL
of	NULL
an	NULL
LPS	NULL
receptor	NULL
or	NULL
for	NULL
other	NULL
reasons	NULL
.	NULL

Since	NULL
LPS	NULL
induces	NULL
production	NULL
of	NULL
TNF-a	NULL
(	NULL
28	NULL
)	NULL
and	NULL
TNF-a	NULL
was	NULL
able	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
our	NULL
HIV-1-CAT	NULL
con-struct	NULL
,	NULL
it	NULL
could	NULL
be	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
LPS	NULL
on	NULL
HIV-1-LTR-driven	NULL
transcription	NULL
is	NULL
indirect	NULL
.	NULL

An	NULL
antibody	NULL
to	NULL
TNF-a	NULL
did	NULL
not	NULL
block	NULL
the	NULL
LPS-induced	NULL
HIV-1-LTR	NULL
CAT	NULL
stimulation	NULL
.	NULL

Moreover	NULL
,	NULL
EMSAs	NULL
demonstrated	NULL
that	NULL
LPS	NULL
activation	NULL
of	NULL
NF-kB	NULL
begins	NULL
within	NULL
30	NULL
min	NULL
or	NULL
less	NULL
of	NULL
treatment	NULL
.	NULL

It	NULL
is	NULL
not	NULL
likely	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
an	NULL
LPS-induced	NULL
increase	NULL
in	NULL
production	NULL
or	NULL
release	NULL
of	NULL
TNF-a	NULL
is	NULL
the	NULL
major	NULL
mechanism	NULL
underlying	NULL
this	NULL
effect	NULL
.	NULL

The	NULL
TNF-a	NULL
promoter	NULL
itself	NULL
has	NULL
«	NULL
B-like	NULL
regions	NULL
(	NULL
32	NULL
)	NULL
,	NULL
and	NULL
consequently	NULL
,	NULL
both	NULL
stimulation	NULL
of	NULL
TNF-a	NULL
and	NULL
stimulation	NULL
of	NULL
HIV-1	NULL
may	NULL
be	NULL
independent	NULL
results	NULL
of	NULL
LPS-mediated	NULL
NF-KB	NULL
activation	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
has	NULL
demonstrated	NULL
that	NULL
LPS-treated	NULL
primary	NULL
macrophages	NULL
produce	NULL
cytokines	NULL
,	NULL
including	NULL
TNF-	NULL
,	NULL
which	NULL
stimulate	NULL
HIV-1	NULL
production	NULL
in	NULL
T	NULL
lymphocytes	NULL
(	NULL
10	NULL
)	NULL
.	NULL

This	NULL
is	NULL
certainly	NULL
a	NULL
possible	NULL
mechanism	NULL
by	NULL
which	NULL
LPS	NULL
stimulation	NULL
of	NULL
some	NULL
monocyte/macrophage	NULL
populations	NULL
might	NULL
affect	NULL
not	NULL
only	NULL
HIV-1	NULL
production	NULL
directly	NULL
in	NULL
monocyte/macrophages	NULL
but	NULL
also	NULL
have	NULL
an	NULL
indirect	NULL
effect	NULL
on	NULL
HIV-1	NULL
replication	NULL
in	NULL
T	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
.	NULL

It	NULL
is	NULL
instructive	NULL
to	NULL
note	NULL
that	NULL
a	NULL
significant	NULL
effect	NULL
on	NULL
HIV-1	NULL
production	NULL
was	NULL
not	NULL
demonstrated	NULL
when	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
was	NULL
treated	NULL
with	NULL
LPS	NULL
alone	NULL
.	NULL

Only	NULL
after	NULL
pretreatment	NULL
with	NULL
GM-	NULL
259	NULL
Pomerantz	NULL
et	NULL
al	NULL
.	NULL

i	NULL
U1	NULL
Jurkat	NULL
r	NULL
1-1	NULL
a	NULL
.	NULL

<	NULL
3	NULL
-	NULL
o	NULL
QU	NULL
Ea	NULL
;	NULL
-	NULL
>	NULL
S3	NULL
E	NULL
on	NULL
o	NULL
|	NULL
-l	NULL
O	NULL
O	NULL
u	NULL
_	NULL
Cu	NULL
+	NULL
+	NULL
m	NULL
on	NULL
oa	NULL
5	NULL
5	NULL
%	NULL
<	NULL
§+++	NULL
TC	NULL
to	NULL
gol	NULL
ol	NULL
L	NULL
a	NULL
m	NULL
-	NULL
n	NULL
mn	NULL
a	NULL
=	NULL
&	NULL
o	NULL
4	NULL
o	NULL
o	NULL
o	NULL
<	NULL
a	NULL
<	NULL
3	NULL
=	NULL
=	NULL
=	NULL
p33	NULL
1	NULL
J	NULL
&	NULL
a	NULL
&	NULL
&	NULL
&	NULL
|	NULL
a	NULL
*P	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
°	NULL
6	NULL
7	NULL
8	NULL
9	NULL
Figure	NULL
7	NULL
.	NULL

EMSA	NULL
of	NULL
U1	NULL
cells	NULL
.	NULL

(	NULL
Lane	NULL
1	NULL
)	NULL
U1	NULL
cells	NULL
,	NULL
no	NULL
treatment	NULL
.	NULL

(	NULL
Lane	NULL
2	NULL
)	NULL
U1	NULL
cells	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
(	NULL
Lane	NULL
3	NULL
)	NULL
U1	NULL
cells	NULL
treated	NULL
with	NULL
GM-CSF	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
(	NULL
Lane	NULL
4	NULL
)	NULL
U1	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
PHA	NULL
(	NULL
2	NULL
pg/ml	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h.	NULL
(	NULL
Lane	NULL
5	NULL
)	NULL
U1	NULL
cells	NULL
treated	NULL
with	NULL
GM-CSF	NULL
for	NULL
24	NULL
h	NULL
then	NULL
LPS	NULL
for	NULL
24	NULL
h.	NULL
(	NULL
Lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
U1	NULL
cells	NULL
pretreated	NULL
with	NULL
GM-CSF	NULL
for	NULL
24	NULL
h	NULL
and	NULL
then	NULL
LPS	NULL
for	NULL
24	NULL
h	NULL
plus	NULL
20	NULL
ng	NULL
of	NULL
unlabeled	NULL
competitor	NULL
(	NULL
comp	NULL
)	NULL
or	NULL
mutant	NULL
competitor	NULL
(	NULL
mut	NULL
.	NULL

comp	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
Lane	NULL
8	NULL
)	NULL
Jurkat	NULL
,	NULL
no	NULL
treatment	NULL
.	NULL

(	NULL
Lane	NULL
9	NULL
)	NULL
Jurkat	NULL
plus	NULL
PMA	NULL
and	NULL
PHA	NULL
for	NULL
2	NULL
h.	NULL
This	NULL
representative	NULL
autoradiograph	NULL
was	NULL
slightly	NULL
overexposed	NULL
to	NULL
properly	NULL
illustrate	NULL
the	NULL
small	NULL
quantity	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
that	NULL
was	NULL
activated	NULL
in	NULL
U1	NULL
cells	NULL
{	NULL
uppermost	NULL
band	NULL
in	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
and	NULL
7	NULL
)	NULL
.	NULL

(	NULL
Closed	NULL
arrowheads	NULL
)	NULL
NF-KB	NULL
band	NULL
;	NULL
(	NULL
open	NULL
arrowheads	NULL
)	NULL
unbound	NULL
probe	NULL
.	NULL

CSF	NULL
,	NULL
which	NULL
has	NULL
been	NULL
noted	NULL
to	NULL
induce	NULL
differentiation	NULL
and	NULL
maturation	NULL
in	NULL
monocytic	NULL
precursor	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
,	NULL
was	NULL
LPS	NULL
able	NULL
to	NULL
stimulate	NULL
high	NULL
levels	NULL
of	NULL
HIV-1	NULL
production	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
the	NULL
U1	NULL
cell	NULL
subclone	NULL
of	NULL
HIV-1-infected	NULL
U937	NULL
cells	NULL
may	NULL
be	NULL
quite	NULL
im-	NULL
mature	NULL
and	NULL
either	NULL
lack	NULL
an	NULL
LPS	NULL
receptor	NULL
or	NULL
some	NULL
component	NULL
of	NULL
the	NULL
proximal	NULL
NF-KB	NULL
activation	NULL
pathway	NULL
induced	NULL
by	NULL
LPS	NULL
.	NULL

Only	NULL
after	NULL
maturation	NULL
by	NULL
GM-CSF	NULL
can	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
respond	NULL
to	NULL
LPS	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
HIV-1	NULL
production	NULL
from	NULL
its	NULL
integrated	NULL
provirus	NULL
.	NULL

As	NULL
with	NULL
the	NULL
HIV-1-LTR	NULL
CAT	NULL
trans-fections	NULL
,	NULL
the	NULL
LPS-effect	NULL
on	NULL
viral	NULL
production	NULL
is	NULL
largely	NULL
a	NULL
direct	NULL
one	NULL
and	NULL
is	NULL
not	NULL
mediated	NULL
via	NULL
a	NULL
release	NULL
of	NULL
TNF-	NULL
.	NULL

An	NULL
anti-TNF-a	NULL
antibody	NULL
was	NULL
able	NULL
to	NULL
decrease	NULL
only	NULL
slightly	NULL
the	NULL
level	NULL
of	NULL
HIV-1	NULL
production	NULL
in	NULL
the	NULL
U1	NULL
cell	NULL
line	NULL
pretreated	NULL
with	NULL
GMCSF	NULL
to	NULL
which	NULL
LPS	NULL
was	NULL
added	NULL
.	NULL

Only	NULL
if	NULL
endogenously	NULL
produced	NULL
TNFa	NULL
is	NULL
more	NULL
difficult	NULL
to	NULL
neutralize	NULL
compared	NULL
with	NULL
exogenous	NULL
TNF-a	NULL
might	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
LPS	NULL
effect	NULL
still	NULL
be	NULL
mediated	NULL
through	NULL
TNF-	NULL
«	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
has	NULL
demonstrated	NULL
that	NULL
pretreating	NULL
primary	NULL
macrophages	NULL
with	NULL
LPS	NULL
may	NULL
protect	NULL
them	NULL
from	NULL
HIV-1	NULL
infec-tion	NULL
,	NULL
possibly	NULL
through	NULL
activation	NULL
(	NULL
13	NULL
)	NULL
.	NULL

This	NULL
study	NULL
is	NULL
not	NULL
at	NULL
variance	NULL
with	NULL
our	NULL
data	NULL
.	NULL

Treatment	NULL
of	NULL
macrophages	NULL
with	NULL
LPS	NULL
before	NULL
infection	NULL
with	NULL
HIV-1	NULL
may	NULL
have	NULL
a	NULL
different	NULL
effect	NULL
on	NULL
HIV-1	NULL
production	NULL
than	NULL
treatment	NULL
of	NULL
chronically	NULL
HIV-1-infected	NULL
monocyte/macrophages	NULL
.	NULL

That	NULL
LPS	NULL
may	NULL
protect	NULL
macrophages	NULL
from	NULL
HIV-1	NULL
infection	NULL
and	NULL
increase	NULL
HIV-1	NULL
production	NULL
from	NULL
chronically	NULL
infected	NULL
monocyte/macrophages	NULL
suggests	NULL
that	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
LPS	NULL
on	NULL
HIV-1	NULL
may	NULL
be	NULL
complex	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-KB	NULL
as	NULL
the	NULL
cellular	NULL
mediator	NULL
of	NULL
the	NULL
LPS	NULL
effect	NULL
on	NULL
HIV-1	NULL
production	NULL
in	NULL
monocyte/macrophage-like	NULL
cells	NULL
is	NULL
yet	NULL
another	NULL
system	NULL
controlled	NULL
by	NULL
this	NULL
transcriptional	NULL
regulator	NULL
(	NULL
for	NULL
review	NULL
see	NULL
reference	NULL
34	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-KB	NULL
does	NULL
not	NULL
require	NULL
protein	NULL
synthesis	NULL
,	NULL
and	NULL
probably	NULL
occurs	NULL
through	NULL
the	NULL
release	NULL
of	NULL
an	NULL
inhibitor	NULL
(	NULL
IxB	NULL
)	NULL
,	NULL
bound	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
free	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
then	NULL
migrate	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
binds	NULL
to	NULL
10	NULL
or	NULL
11	NULL
bp	NULL
enhancer-motifs	NULL
present	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
promoters	NULL
.	NULL

These	NULL
include	NULL
HIV-1	NULL
,	NULL
CMV	NULL
,	NULL
IFN-	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
the	NULL
human	NULL
Ig	NULL
enhancer	NULL
,	NULL
to	NULL
name	NULL
but	NULL
a	NULL
few	NULL
(	NULL
34	NULL
)	NULL
.	NULL

NF-KB	NULL
activation	NULL
takes	NULL
place	NULL
via	NULL
more	NULL
than	NULL
one	NULL
pathway	NULL
(	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

That	NULL
LPS	NULL
and	NULL
phorbol	NULL
esters	NULL
have	NULL
very	NULL
different	NULL
time	NULL
courses	NULL
to	NULL
induce	NULL
NF-KB	NULL
in	NULL
U937	NULL
and	NULL
THP-1	NULL
cell	NULL
lines	NULL
might	NULL
suggest	NULL
a	NULL
different	NULL
pathway	NULL
,	NULL
as	NULL
has	NULL
recently	NULL
been	NULL
considered	NULL
for	NULL
TNF-ox	NULL
and	NULL
phorbol	NULL
esters	NULL
(	NULL
6	NULL
)	NULL
.	NULL

LPS	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
minimally	NULL
increase	NULL
(	NULL
1.5-fold	NULL
)	NULL
HIV-1	NULL
production	NULL
in	NULL
chronically	NULL
infected	NULL
THP-1	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
.	NULL

We	NULL
have	NULL
confirmed	NULL
these	NULL
findings	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
but	NULL
would	NULL
suggest	NULL
that	NULL
the	NULL
extremely	NULL
low	NULL
HIV-1-producing	NULL
monocyte/macrophage-like	NULL
cell	NULL
line	NULL
,	NULL
U1	NULL
,	NULL
is	NULL
a	NULL
better	NULL
model	NULL
in	NULL
which	NULL
to	NULL
study	NULL
the	NULL
control	NULL
of	NULL
HIV-1	NULL
production	NULL
.	NULL

Most	NULL
investigators	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
demonstrate	NULL
consistent	NULL
increases	NULL
in	NULL
HIV-1	NULL
production	NULL
,	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
agents	NULL
,	NULL
in	NULL
un-cloned	NULL
,	NULL
chronically	NULL
infected	NULL
ceﬁ	NULL
lines	NULL
(	NULL
11	NULL
)	NULL
.	NULL

This	NULL
appears	NULL
to	NULL
be	NULL
due	NULL
to	NULL
the	NULL
vast	NULL
heterogeneity	NULL
of	NULL
these	NULL
cell	NULL
populations	NULL
and	NULL
the	NULL
relatively	NULL
high	NULL
level	NULL
of	NULL
viral	NULL
production	NULL
noted	NULL
in	NULL
such	NULL
chronically	NULL
infected	NULL
cell	NULL
lines	NULL
even	NULL
at	NULL
baseline	NULL
levels	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Many	NULL
patients	NULL
with	NULL
or	NULL
at	NULL
risk	NULL
for	NULL
HIV-1	NULL
infection	NULL
have	NULL
episodes	NULL
of	NULL
localized	NULL
bacterial	NULL
infections	NULL
or	NULL
frank	NULL
bacteremias	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Endotoxin	NULL
might	NULL
reach	NULL
levels	NULL
,	NULL
in	NULL
various	NULL
locations	NULL
of	NULL
the	NULL
body	NULL
,	NULL
demonstrated	NULL
to	NULL
induce	NULL
HIV-1	NULL
production	NULL
in	NULL
monocyte/macrophage-like	NULL
cells	NULL
in	NULL
this	NULL
study	NULL
.	NULL

In	NULL
normal	NULL
individuals	NULL
,	NULL
endotoxin	NULL
is	NULL
cleared	NULL
by	NULL
the	NULL
reticuloendothelial	NULL
system	NULL
of	NULL
the	NULL
liver	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
small	NULL
amount	NULL
of	NULL
endotoxin	NULL
made	NULL
by	NULL
gram-negative	NULL
bacteria	NULL
always	NULL
found	NULL
in	NULL
the	NULL
gut	NULL
is	NULL
continuously	NULL
cleared	NULL
by	NULL
these	NULL
mononuclear	NULL
phagocytic	NULL
cells	NULL
.	NULL

of	NULL
the	NULL
liver	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
demonstrate	NULL
that	NULL
LPS	NULL
at	NULL
concentrations	NULL
as	NULL
low	NULL
as	NULL
10	NULL
pg/ml	NULL
might	NULL
affect	NULL
HIV-1	NULL
replication	NULL
.	NULL

In	NULL
HIV-1-infected	NULL
individuals	NULL
,	NULL
this	NULL
amount	NULL
of	NULL
LPS	NULL
might	NULL
stimulate	NULL
HIV-1	NULL
production	NULL
from	NULL
monocyte/macrophages	NULL
located	NULL
in	NULL
liver	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
other	NULL
organs	NULL
.	NULL

Monocyte/macrophages	NULL
may	NULL
be	NULL
the	NULL
major	NULL
cell	NULL
type	NULL
infected	NULL
with	NULL
HIV-1	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Whether	NULL
exposure	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
LPS	NULL
may	NULL
lead	NULL
to	NULL
increased	NULL
HIV-1	NULL
production	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
,	NULL
and	NULL
subsequent	NULL
clinical	NULL
deterioration	NULL
,	NULL
warrants	NULL
future	NULL
studies	NULL
.	NULL

We	NULL
thank	NULL
Drs	NULL
.	NULL

Sankar	NULL
Ghosh	NULL
,	NULL
Mark	NULL
Muesing	NULL
,	NULL
Anthony	NULL
De	NULL
Franco	NULL
,	NULL
and	NULL
Towia	NULL
Libermann	NULL
for	NULL
critical	NULL
discussions	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Michael	NULL
Lenardo	NULL
for	NULL
providing	NULL
some	NULL
oligonucleotides	NULL
and	NULL
Dr.	NULL
Jacqueline	NULL
Pierce	NULL
for	NULL
providing	NULL
some	NULL
of	NULL
the	NULL
plasmids	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Patricia	NULL
Waddy	NULL
for	NULL
excellent	NULL
secretarial	NULL
assistance	NULL
.	NULL

R.	NULL
J.	NULL
Pomerantz	NULL
is	NULL
funded	NULL
under	NULL
Physician	NULL
Scientist	NULL
Award	NULL
AI-00930	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
U.S.	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI-26463	NULL
and	NULL
HL-43510	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Or	NULL
.	NULL

Roger	NULL
J.	NULL
Pomerantz	NULL
,	NULL
Whitehead	NULL
Institute	NULL
for	NULL
Biomedical	NULL
Research	NULL
,	NULL
Nine	NULL
Cambridge	NULL
Center	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
02142	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
23	NULL
February	NULL
1990	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Ho	NULL
,	NULL
D.D	NULL
.	NULL

,	NULL
R.J.	NULL
Pomerantz	NULL
,	NULL
and	NULL
J.C.	NULL
Kaplan	NULL
.	NULL

1987	NULL
.	NULL

Pathogen-esis	NULL
of	NULL
infection	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

Med	NULL
.	NULL

317:278	NULL
.	NULL

2	NULL
.	NULL

Fauci	NULL
,	NULL
A.S.	NULL
1988	NULL
.	NULL

The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
:	NULL
infec-	NULL
tivity	NULL
and	NULL
mechanisms	NULL
of	NULL
pathogenesis	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

239:617	NULL
.	NULL

3	NULL
.	NULL

Cullen	NULL
,	NULL
BR	NULL
.	NULL

,	NULL
and	NULL
W.C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Regulatory	NULL
pathways	NULL
governing	NULL
HIV-1	NULL
replication	NULL
.	NULL

Cell	NULL
.	NULL

58:423	NULL
.	NULL

260	NULL
Lipopolysaccharide	NULL
and	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20.	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcrip-	NULL
tion	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

326:711.	NULL
.	NULL

Duh	NULL
,	NULL
E.J	NULL
.	NULL

,	NULL
W.J	NULL
.	NULL

Maury	NULL
,	NULL
TM	NULL
.	NULL

Folks	NULL
,	NULL
A.S.	NULL
Fauci	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rabson	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
activates	NULL
HIV	NULL
Type	NULL
I	NULL
through	NULL
induction	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
NF-KB	NULL
sites	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:5974.	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
x	NULL
and	NULL
interleukin	NULL
I	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2336.	NULL
.	NULL

Griffin	NULL
,	NULL
G.E	NULL
.	NULL

,	NULL
K.	NULL
Leung	NULL
,	NULL
TM	NULL
.	NULL

Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.J	NULL
.	NULL

Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

339:70.	NULL
.	NULL

Folks	NULL
,	NULL
TM	NULL
.	NULL

,	NULL
K.A	NULL
.	NULL

Clouse	NULL
,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
J.H	NULL
.	NULL

Kehrl	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
&	NULL
induces	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2365.	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
C.A	NULL
.	NULL

Dinarello	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Cytokine	NULL
induced	NULL
expression	NULL
of	NULL
HIV-1	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promonocyte	NULL
cell	NULL
line	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

238:800	NULL
.	NULL

Clouse	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
D.	NULL
Powell	NULL
,	NULL
I.	NULL
Washington	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
K.	NULL
Strebel	NULL
,	NULL
W.	NULL
Farrar	NULL
,	NULL
B.	NULL
Barstad	NULL
,	NULL
J.	NULL
Kovacs	NULL
,	NULL
A.S.	NULL
Fauci	NULL
,	NULL
and	NULL
T.M	NULL
.	NULL

Folks	NULL
.	NULL

1989	NULL
.	NULL

Monokine	NULL
regulation	NULL
of	NULL
HIV-1	NULL
expression	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
human	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:431	NULL
.	NULL

Pauza	NULL
,	NULL
C.D	NULL
.	NULL

,	NULL
J.	NULL
Galindo	NULL
,	NULL
and	NULL
D.D	NULL
.	NULL

Richman	NULL
.	NULL

1988	NULL
.	NULL

HIV	NULL
infection	NULL
of	NULL
monoblastoid	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:3558	NULL
.	NULL

Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
W.A	NULL
.	NULL

O'Brien	NULL
,	NULL
J.Q	NULL
.	NULL

Zhao	NULL
,	NULL
DW	NULL
.	NULL

Golde	NULL
,	NULL
J.C.	NULL
Gasson	NULL
,	NULL
and	NULL
I.SY	NULL
.	NULL

Chen	NULL
.	NULL

1988	NULL
.	NULL

Cytokines	NULL
alter	NULL
production	NULL
of	NULL
HIV-1	NULL
from	NULL
primary	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

241:1673	NULL
.	NULL

Kornbluth	NULL
,	NULL
R.S	NULL
.	NULL

,	NULL
P.S	NULL
.	NULL

Oh	NULL
,	NULL
J.R.	NULL
Munis	NULL
,	NULL
PH	NULL
.	NULL

Cleveland	NULL
,	NULL
and	NULL
D.D	NULL
.	NULL

Richman	NULL
.	NULL

1986	NULL
.	NULL

Interferons	NULL
and	NULL
bacterial	NULL
lipopolysaccharide	NULL
protect	NULL
macrophages	NULL
from	NULL
productive	NULL
infection	NULL
by	NULL
HIV	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:1137	NULL
.	NULL

Perno	NULL
,	NULL
C.F	NULL
.	NULL

,	NULL
R.	NULL
Yarchoan	NULL
,	NULL
D.A	NULL
.	NULL

Cooney	NULL
,	NULL
N.R	NULL
.	NULL

Hartman	NULL
,	NULL
D.S.A	NULL
.	NULL

Webb	NULL
,	NULL
Z.	NULL
Hao	NULL
,	NULL
H.	NULL
Mitsuya	NULL
,	NULL
D.G	NULL
.	NULL

Johns	NULL
,	NULL
and	NULL
S.	NULL
Broder	NULL
.	NULL

1989	NULL
.	NULL

Replication	NULL
of	NULL
HIV	NULL
in	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:933	NULL
.	NULL

Schnittman	NULL
,	NULL
S	NULL
$	NULL
.M	NULL
.	NULL

,	NULL
M.C	NULL
.	NULL

Psallidopoulos	NULL
,	NULL
H.C.	NULL
Lane	NULL
,	NULL
L.	NULL
Thompson	NULL
,	NULL
M.	NULL
Baseler	NULL
,	NULL
F.	NULL
Massari	NULL
,	NULL
C.H	NULL
.	NULL

Fox	NULL
,	NULL
N.P	NULL
.	NULL

Salzman	NULL
,	NULL
and	NULL
A.S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
reservoir	NULL
for	NULL
HIV-1	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
is	NULL
a	NULL
T	NULL
cell	NULL
that	NULL
maintains	NULL
expression	NULL
of	NULL
CD4	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

245:305	NULL
.	NULL

Wiley	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
R.D	NULL
.	NULL

Schrier	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
,	NULL
PNW	NULL
.	NULL

Lampert	NULL
,	NULL
and	NULL
M.B.A.	NULL
Oldstone	NULL
.	NULL

1986	NULL
.	NULL

Cellular	NULL
localization	NULL
of	NULL
HIV	NULL
infection	NULL
within	NULL
brains	NULL
of	NULL
AIDS	NULL
patients	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

83:7089	NULL
.	NULL

Pomerantz	NULL
,	NULL
R.J.	NULL
,	NULL
SM	NULL
.	NULL

de	NULL
la	NULL
Monte	NULL
,	NULL
S.P	NULL
.	NULL

Donegan	NULL
,	NULL
TR	NULL
.	NULL

Rota	NULL
,	NULL
MW	NULL
.	NULL

Vogt	NULL
,	NULL
D.E	NULL
.	NULL

Craven	NULL
,	NULL
and	NULL
M.S	NULL
.	NULL

Hirsch	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
of	NULL
the	NULL
uterine	NULL
cervix	NULL
.	NULL

Ann	NULL
.	NULL

Int	NULL
.	NULL

Med	NULL
.	NULL

108:321	NULL
.	NULL

Sundstrom	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
K.	NULL
Nilsson	NULL
.	NULL

1976	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
histiocytic	NULL
lymphoma	NULL
cell	NULL
line	NULL
(	NULL
U937	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
17:565	NULL
.	NULL

Tsuchiya	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Yamabe	NULL
,	NULL
Y.	NULL
Yamaguchi	NULL
,	NULL
Y.	NULL
Kobayashi	NULL
,	NULL
T.	NULL
Konno	NULL
,	NULL
and	NULL
K.	NULL
Tada	NULL
.	NULL

1980	NULL
.	NULL

Establishment	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
acute	NULL
monocyte	NULL
leukemia	NULL
cell	NULL
line	NULL
.	NULL

(	NULL
THP-1	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
26:171	NULL
.	NULL

Nagasawa	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Howatson	NULL
,	NULL
and	NULL
TK	NULL
.	NULL

Mak	NULL
.	NULL

1981	NULL
.	NULL

Induction	NULL
261	NULL
Pomerantz	NULL
et	NULL
al	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37.	NULL
of	NULL
human	NULL
malignant	NULL
T-lymphoblastic	NULL
cell	NULL
lines	NULL
Molt-3	NULL
and	NULL
Jurkat	NULL
by	NULL
12-0-tetra	NULL
decanoylphorbol-13-acetate	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

109:181	NULL
.	NULL

Pierce	NULL
,	NULL
J.W	NULL
.	NULL

,	NULL
M.	NULL
Lenardo	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Oligonucleotide	NULL
that	NULL
binds	NULL
nuclear	NULL
factor	NULL
NF-KB	NULL
acts	NULL
as	NULL
a	NULL
lymphoid	NULL
specific	NULL
and	NULL
inducible	NULL
enhancer	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

85:1482	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.E	NULL
.	NULL

Kingston	NULL
,	NULL
D.D	NULL
.	NULL

Moore	NULL
,	NULL
J.G	NULL
.	NULL

Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
.	NULL

1989	NULL
.	NULL

Current	NULL
Protocols	NULL
in	NULL
Molecular	NULL
Biology	NULL
.	NULL

Vol	NULL
.	NULL

I.	NULL
John	NULL
Wiley	NULL
and	NULL
Sons	NULL
,	NULL
New	NULL
York	NULL
.	NULL

9.9.6	NULL
.	NULL

Bradford	NULL
,	NULL
M.M	NULL
.	NULL

1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
.	NULL

Biockem	NULL
.	NULL

72:248	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
,	NULL
L.F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.H	NULL
.	NULL

Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyl-trans-ferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044	NULL
.	NULL

Baeuerle	NULL
,	NULL
PA.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

I	NULL
«	NULL
B	NULL
:	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

242:540	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
46:705	NULL
.	NULL

Dignam	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
R.M	NULL
.	NULL

Lebowitz	NULL
,	NULL
and	NULL
R.G	NULL
.	NULL

Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475	NULL
.	NULL

Kornbluth	NULL
,	NULL
R.S	NULL
.	NULL

,	NULL
and	NULL
T.S	NULL
.	NULL

Edgington	NULL
.	NULL

1986	NULL
.	NULL

TNF	NULL
production	NULL
by	NULL
human	NULL
monocytes	NULL
is	NULL
a	NULL
regulated	NULL
event	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

137:2585	NULL
.	NULL

Kiener	NULL
,	NULL
P.	NULL
,	NULL
F.	NULL
Marek	NULL
,	NULL
G.	NULL
Rodgers	NULL
,	NULL
P.-F.	NULL
Lin	NULL
,	NULL
G.	NULL
Ware	NULL
,	NULL
and	NULL
J.	NULL
Desiderio	NULL
.	NULL

1988	NULL
.	NULL

Induction	NULL
of	NULL
TNF	NULL
,	NULL
IFNy	NULL
and	NULL
acute	NULL
lethality	NULL
in	NULL
mice	NULL
by	NULL
toxic	NULL
and	NULL
nontoxic	NULL
forms	NULL
of	NULL
Lipid	NULL
A.	NULL
J.	NULL
Immunol	NULL
.	NULL

141:870	NULL
.	NULL

Baver	NULL
,	NULL
J.	NULL
,	NULL
U.	NULL
Ganter	NULL
,	NULL
T.	NULL
Geiger	NULL
,	NULL
U.	NULL
Jacobshagen	NULL
,	NULL
T.	NULL
Hirano	NULL
,	NULL
T.	NULL
Matsuda	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
T.	NULL
Andus	NULL
,	NULL
G.	NULL
Acs	NULL
,	NULL
W.	NULL
Gerok	NULL
,	NULL
and	NULL
G.	NULL
Ciliberto	NULL
.	NULL

1988	NULL
.	NULL

Regulation	NULL
of	NULL
Interleukin-6	NULL
expression	NULL
in	NULL
cultured	NULL
human	NULL
blood	NULL
monocytes	NULL
and	NULL
macrophages	NULL
.	NULL

Blood	NULL
.	NULL

72:1134	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Inducibility	NULL
of	NULL
«	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-KB	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
.	NULL

47:921	NULL
.	NULL

Shakhov	NULL
,	NULL
A.N	NULL
.	NULL

,	NULL
M.	NULL
Collart	NULL
,	NULL
P.	NULL
Vassalli	NULL
,	NULL
S.A.	NULL
Nedospasov	NULL
,	NULL
and	NULL
CV	NULL
.	NULL

Jongeneel	NULL
.	NULL

1990	NULL
.	NULL

«	NULL
B-type	NULL
enhancers	NULL
are	NULL
involved	NULL
in	NULL
LPS-mediated	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
TNFa	NULL
gene	NULL
in	NULL
primary	NULL
macrophages	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:35	NULL
.	NULL

Metcalf	NULL
,	NULL
D.	NULL
,	NULL
C.D	NULL
.	NULL

Begley	NULL
,	NULL
G.R	NULL
.	NULL

Johnson	NULL
,	NULL
N.A	NULL
.	NULL

Nicola	NULL
,	NULL
M.A	NULL
.	NULL

Vadas	NULL
,	NULL
A.F	NULL
.	NULL

Lopez	NULL
,	NULL
D.J	NULL
.	NULL

Williamson	NULL
,	NULL
G.G	NULL
.	NULL

Wong	NULL
,	NULL
S.C.	NULL
Clark	NULL
,	NULL
and	NULL
E.A	NULL
.	NULL

Wang	NULL
.	NULL

1986	NULL
.	NULL

Biologic	NULL
properties	NULL
in	NULL
vitro	NULL
of	NULL
a	NULL
recombinant	NULL
human	NULL
GM-CSF	NULL
.	NULL

Blood	NULL
.	NULL

67:37	NULL
.	NULL

Lenardo	NULL
,	NULL
M.J.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

NF-KB	NULL
:	NULL
a	NULL
pleiotropic	NULL
mediator	NULL
of	NULL
inducible	NULL
and	NULL
tissue-specific	NULL
gene	NULL
control	NULL
.	NULL

Cell	NULL
.	NULL

58:227	NULL
.	NULL

Molina	NULL
,	NULL
J-M	NULL
,	NULL
DT	NULL
.	NULL

Scadden	NULL
,	NULL
R.	NULL
Byrn	NULL
,	NULL
C.	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1989	NULL
.	NULL

Production	NULL
of	NULL
TNFa	NULL
and	NULL
IL-1	NULL
by	NULL
monocytic	NULL
cells	NULL
infected	NULL
with	NULL
HIV	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84:733	NULL
.	NULL

Jacobs	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
JW.M	NULL
.	NULL

God	NULL
,	NULL
HW	NULL
.	NULL

Murray	NULL
,	NULL
R.B	NULL
.	NULL

Roberts	NULL
,	NULL
and	NULL
D.	NULL
Armstrong	NULL
.	NULL

1985	NULL
.	NULL

Salmonella	NULL
infections	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Ann	NULL
.	NULL

Int	NULL
.	NULL

Med	NULL
.	NULL

102:186	NULL
.	NULL

Farrer	NULL
,	NULL
W.E	NULL
.	NULL

,	NULL
and	NULL
L.M	NULL
.	NULL

Corwin	NULL
.	NULL

1966	NULL
.	NULL

The	NULL
essential	NULL
role	NULL
of	NULL
the	NULL
liver	NULL
in	NULL
detoxification	NULL
of	NULL
endotoxin	NULL
.	NULL

Ann	NULL
.	NULL

NY	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

133:668	NULL
.	NULL

